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Abstract
Antibodies, also known as immunoglobulins (Ig), are large, Y-shaped proteins produced by the
immune system to neutralize foreign molecules (antigens) that enter the host body. Utilizing
modern instruments such as surface plasmon resonance (SPR) and liquid chromatography-mass
spectrometry (LC-MS) holds a great potential in antibody related research. This thesis mainly
focuses on three parts: (1) development of SPR imaging methodology for measurement of specific
IgE antibodies against peanut protein epitopes in human serum, (2) development of new method
for characterizing surface immobilized antibody orientation, and (3) development of a set of LCMS methods for bioanalysis of proteins and antibodies which isolated from human serum by
selective nanoparticles.
Chapter 1 is a brief introduction which gives the goals and significance of the thesis. It also has an
overview of antibodies and IgE antibody mediated food allergy. The state-of-art techniques used
in this thesis, SPR and LC-MS, are included at the end.
Chapter 2 describes a method that first captures IgE antibodies from serum by using anti-IgE
decorated magnetic particles, then measures their binding to specific epitopes from peanut allergen
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proteins using an arrayed SPR imaging. The method cataloged peanut specific IgE antibodies in a
set of patient samples and showed excellent correlation with clinical diagnostics.
Chapter 3 puts forward a novel method utilizing limited proteolysis on surface immobilized
antibodies to probe the antibody orientation. The limiting protease access to the antibody layer
resulted in different compositions of proteolytic peptides which can be analyzed by LC-MS/MS
and the orientation information could thus be interpreted.
Chapter 4 shows several MS-based protein/antibody determination methods in the development of
magnetic nanoparticles bearing selective protein binding nanopockets. Quantitative bioanalysis of
proteins and antibodies were conducted by LC-MS and our specially synthesized nanoparticles
exhibited excellent performance than columns or beads from the commercial source.
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Chapter 1 Overview of Antibody Related Research and Instruments
Used in This Thesis

1

1.1 Purpose of Study and Significance
Antibodies, also known as immunoglobulins (Ig), are proteins produced by immune system for
neutralizing antigens. Profiling of antibodies with modern instruments such as surface plasmon
resonance (SPR) and liquid chromatography–mass spectrometry (LC-MS) holds a great potential
to picture an individual's antigen exposure history and reveal vital information about individual's
immune system. On the other side, the orientation of surface immobilized proteins, such as capture
antibodies, plays a significant role in the performance of immunoassays, as the optimum capture
efficiency requires the two antigen binding sites be directed toward the solution phase. While there
are a number of reports claiming oriented antibodies give the better performance, the number of
techniques that are able to characterize antibody orientation is limited.
In this dissertation, we would like to address several different aspects regarding antibodies: (i)
distinguishing peanut-specific IgE antibodies in an epitope resolved manner using surface
plasmon resonance imaging (SPRi) technique; (ii) characterizing surface-immobilized
antibody orientation at peptide level using limited proteolysis followed by liquid
chromatography–mass spectrometry (LC-MS) analysis; and (iii) using LC-MS to
quantitatively analyze the proteins and antibodies isolated from human serum by selective
nanoparticles. In the first two aspects, superparamagnetic particles (MP) labeled with thousands
of antibodies are used because they provide a compelling approach for efficient target capture,
enrichment and convenient separation. And in the last aspect, we specially constructed magnetic
nanoparticles with selective protein binding nanopockets and used them for albumin depletion and
antibody purification from human serum. NO human or animal subjects were used through the
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entire dissertation research. The general information is given in this chapter as an introduction;
details about our research are described in the following chapters.

1.2 Overview of Antibody
This overview section of antibody aims to act as a basic introduction to antibodies including their
structures, classes, production, purification, and conjugations.1,2

1.2.1 Structure of an antibody molecule
In general, an antibody molecule performs two primary functions, which thus correspond to two
major individual regions in their structure.1-5 One part of the antibody, the fragment antigenbinding (Fab) region, specifically recognizes and binds to the antigens; while the other part of the
antibody, known as the fragment crystallizable (Fc) region, interacts with cell surface Fc receptors
and some proteins in the complement system, which allows antibodies to activate the immune
system.
Structurally, an antibody molecule is a large protein with two identical pairs of heavy and light
chains linked by disulfide bonds (exceptions include certain antibodies found in sharks 6 and
camelids7 that lack light chains). The two light chain with their nearby heavy chain parts form two
individual Fab arms containing identical antigen-binding domains. The two Fab regions are
attached to a flexible hinge region, followed by the stem of the antibody, the Fc region, presenting
a classical “Y” shape. The chains are also categorized into constant (C) and variable (V) regions
according to the sequence conservation. In detail, the heavy and light chains constitute a series of
3

discrete protein domains as known as immunoglobulin folds (VL, CL, VH, CH1, CH2, and CH3
domains in Figure 1.1A and 1.1B).1-3,8 Each immunoglobulin fold consists a pair of β sheets which
are made by antiparallel β strands. In the immunoglobulin fold of either VL or VH domain, three
loops present at the same end of the structure to connect the β strands. These loops form a potential
binding surface for antigens and contain the hypervariable sequences (referred to as hypervariable
loops or complementarity determining regions, CDR), so they enable antibodies to recognize and
bind to an almost unlimited number of antigens. It is worthy to note that a paratope is referred to
as a part of an antibody which recognizes and binds to an antigen while an epitope is referred to
as the part of the antigen to which the paratope binds.9 The actual paratope is located at the CDRs
but not necessarily referred to as the whole six CDRs (three in VL domain and three in VH domain).
It is more likely composed of certain amino acids individually from one or two of the three CDRs
on each variable domains and form a conformational structure.
As illustrated in Figure 1.1A and 1.1B, the association of the heavy and light chains is not only
due to the disulfide linkage but also enhanced by the interactions between pairs of VH and VL, CH1
and CL, and the two CH3 domains, respectively. However, the two CH2 domains do not interact;
instead, two carbohydrate side chains attach to the CH2 domains and stuck between the two heavy
chains.1,3 Such glycosylation is a common post-translational modification for antibodies and it
plays a significant role for immune system functions, which is beyond the current scope of this
dissertation.10,11 However, as the carbohydrate side chains locate in the Fc region, they could
become a good target for bioconjugation.12,13

4

Figure 1.1 Structure of an antibody molecule: (A) A ribbon diagram of a mouse IgG1 antibody
(PDB entry 1IGY) shows the secondary structure of the four polypeptide chains. The carbohydrate
side chains are in magenta. The enlarged picture presents an immunoglobulin fold with the β-sheet
framework in green and three hypervariable loops (CDRs) in brown. The CDRs are numbered
sequentially from N-terminus to C-terminus. The PyMOL Molecular Graphics System, Version
1.8 Schrödinger, LLC, was used. (B) A cartoon version of an antibody molecule illustrating the
four chains in an antibody and the individual domains paring between each chain. (C) A simplified
schematic representation of an antibody molecule that will be used throughout this dissertation.

1.2.2 Classes and subclasses of antibodies
Mammal antibodies have five antibody isotypes or classes known as IgA, IgD, IgE, IgG, and IgM
antibodies, with an “Ig” prefix as immunoglobulin, a name that has an interchangeable meaning
with the antibody.1-3 The classes are based on the different heavy chains they contain, named
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alphabetically: α (alpha), γ (gamma), δ (delta), ε (epsilon), and μ (mu), which gives rise to IgA,
IgG, IgD, IgE, and IgM antibodies, respectively. These antibodies differ in many properties
(Figure 1.2 and Table 1.1) but still they share a similar structure and some functions. The light
chains fall into two classes in mammals, κ (kappa) and λ (lambda), with κ chain being the more
common one in human and mouse (% κ : λ = 67 : 33 and 99 : 1, respectively).3
Some antibodies can even be divided into subclasses. For example, human IgG antibody consists
four subclasses (IgG1, IgG2, IgG3, and IgG4 antibodies) each containing a different heavy chain.14
They are highly homologous, but they still have unique peptides for individual subclass
identification and quantification as we used in Chapter 4. Mouse IgG antibody consists the
subclasses including IgG1, IgG2a, IgG2b, IgG2c, and IgG3 antibodies while rat IgG antibody
consists the subclasses including IgG1, IgG2a, IgG2b, and IgG2c antibodies.1

Figure 1.2 Schematic representation of the five antibody (immunoglobulin) classes in mammals
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Table 1.1 Important properties of five antibody (immunoglobulin) classes in mammals 2,3
Antibody
classes

IgG

IgM

IgA

IgD

IgE

γ

μ

α

δ

ε

150

950

160 [b]

180 [c]

190

Structure

Monomer

Pentamer

Monomers to
tetramers [d]

Monomer

Monomer

Valency

2

10

2, 4, 6, or 8

2

2

IgG1, 2, 3, 4

None

IgA1, 2

None

None

10 - 16

0.5 - 2

1.0 - 4.0

0 - 0.4

0.00001 0.0004

Abundance in
human serum
antibodies [a]

80%

6%

13%

0.2%

0.002%

Carbohydrate
content [a]

3%

12%

10%

13%

13%

Distribution

Blood and
lymph;
Mainly blood Mainly blood
Secretions
and lymph
and lymph
(tears, saliva,
milk)

Blood and
lymph;
Lymphocyte
surface

Blood; Mast
cell and
basophil
surface

Function

Secondary
response

Unclear

Allergy
mediator

Heavy chain
type
Molecular
weight (kDa) [a]

Subclasses
Concentration
in human serum
(mg mL-1) [a]

Primary
response

Mucosal
response

[a] approximately; [b]monomer; [c] secreted form; [d] trimers and tetramers are rare, dimers are
more common.

1.2.3 IgE antibody mediated allergic reaction
IgE antibodies are normally of extremely low concentration in the serum, but they are mainly
found on the surface of basophils and mast cells. They may primarily defend against parasitic
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invasion, and they also mediate type I hypersensitivity reactions, which manifest in various allergic
diseases.15-18
In the type I hypersensitivity reactions (Figure 1.3), with the help of antigen-presenting cell (APC),
T helper 2 (Th2) cells, and numerous stimulatory signals, B-cells are stimulated to become plasma
cells and secrete IgE antibodies specific to an antigen (allergen). Then the IgE antibodies locate
onto FcεRI receptors within the surface of mast cells and basophils to achieve the sensitization
step. The secondary exposure to the same allergen gathers every two bound IgE antibodies on the
cells and results in the dimerization of FcεRI receptors. Sufficient FcεRI aggregations initiate
complex signaling events in the sensitized cells, which cause a large number of cellular mediators,
such as histamine and serotonin, to release from storage granules (degranulation), ultimately
resulting in either local or systemic allergic reactions.

Figure 1.3 Schematic representation of IgE antibody mediated allergic reaction
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Regarding the interaction between IgE antibodies and allergens, there is a model initially proposed
by Aalberse et al.19 and later demonstrated experimentally by Christensen et al.20. As illustrated in
Figure 1.4, such allergen-mediated IgE-dependent cross-linking of FcεRI receptors and effector
cell stimulation is presumably divided into four steps. Firstly, IgE antibodies are anchored onto
effector cell surface via the strong interactions between IgE antibody Fc region and the FcεRI
receptor. Secondly, the allergen is initially captured by a high-affinity anchored IgE antibody and
confined onto the cell surface. Thirdly, the allergen-IgE complex encounters another FcεRI-bound
IgE antibody. Finally, even if the second IgE antibody is of low affinity for allergen, the allergentwo IgE antibodies complex can still cause efficient cross-linking of two FcεRI receptors and
trigger the effector cell. This model has several features, which include (1) the two IgE antibodies
have the same high affinity for the FcεRI receptors, but the affinity requirements for the first IgE
antibody are higher than for the second one; (2) the effector cell can be triggered by a single IgE
antibody of high-affinity in combination with one or more IgE antibodies of low-affinity; (3) these
two IgE antibodies must bind to different epitopes of allergen in order to achieve cellular
stimulatory signals; (4) the binding of allergen-IgE complex to the second (low-affinity) antibodies
is more critical for this whole process.
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Figure 1.4 A schematic model of allergen-mediated IgE-dependent cross-linking of FcεRI
receptors and effector cell stimulation

1.2.4 The production, purification, and conjugation of antibodies 2
Antibody production is a conceptually simple but procedurally complicated process as it involves
a complex biological system (immunity of a living organism) which is able to generate tremendous
numbers and kinds of antibodies which can bind to an almost unlimited number of antigens.
Polyclonal antibodies are recovered directly from the serum of antigen immunized laboratory or
farm animals.21 Monoclonal antibodies are produced by hybridoma cell culture, which is made by
fusing antibody-secreting spleen cells from immunized mice with the immortal myeloma cells.22
Polyclonal antibodies bind to multiple epitopes so they have different various regions while
monoclonal antibodies are identical and they bind to the same epitope and have the same affinity
for that epitope.
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Antibody purification aims at recovering antibody from serum (polyclonal antibody), or
hybridoma cell culture supernatant (monoclonal antibody). In industry, a combination of threecolumn chromatography process is typically employed, which includes antigen affinity
chromatography (for the purification of polyclonal antibodies) or protein A affinity
chromatography (for the purification of monoclonal antibodies) as an initial capture step, followed
by cation exchange and anion exchange chromatography as polishing steps and a virus filtration
step, respectively.23 In the laboratory of microscale sample preparation, protein A-based affinity
columns, resins, and magnetic beads are extensively used for antibody purification, since the
protein A ligand has a high affinity for the Fc region of antibodies, which enables the efficient
antibody capture.24
Antibody conjugation involves link antibodies to any molecules or media via covalent or
noncovalent bonds. A typical antibody contains primary amine (-NH2) and carboxyl (-COOH)
groups, which are abundant and well distributed over the antibody surface. And it also possesses
sulfhydryl (-SH) groups in the form of disulfide bonds, and carbohydrate/sugar moieties at each
of the two CH2 regions, which could yield aldehyde groups (-CHO) via specific oxidation. Those
four groups are major target for antibody conjugation, especially the last two since they have
specific locations on antibody molecules. There are other tremendous approaches to achieve
antibody conjugation with other molecules, which are summarized by many reviews.13, 25 - 27
Currently, site-selective conjugation and conjugation with clear stoichiometry are the goals of
modern antibody conjugation protocols, especially for manufacturing antibody-drug conjugates
(ADCs).25-27
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1.3 Surface plasmon resonance imaging (SPRi)
Surface plasmon resonance (SPR) is a powerful technique that allows real-time, label-free
detection of biomolecular interactions.28-30 In an SPR experiment, one of the interacting partners
is immobilized onto the sensor surface while its potential interacting partner(s) is delivered to the
surface through a series of flow cells (e.g. microfluidic system). The biomolecular interactions that
SPR can monitor are not limited to protein-protein interactions but also include interactions
between DNA-DNA, protein-DNA, and even protein-protein functionalized particles. 31-34 SPR
technique currently is a good standard for investigating biomolecular interactions, such as (1) to
identify genuine interactions between two molecules, (2) to determine the binding affinity (which
is interpreted as dissociation constant, Kd) of the interactions, (3) to measure the association and
dissociation rate constants (ka and kd, respectively). In addition, such biomolecular interactions
can be exploited to quantify the concentration of the interacting partner(s).

1.3.1 SPR theory and SPRi
SPR occurs when the plane-polarized light is incident onto a thin metal film, such as gold (Au),
under total internal reflection (TIR) conditions. When both of the energy (frequency) and the
momentum of photons in the incident are proper, the photons will be absorbed by the “sea” of free
electrons (outer shell and conduction-band electrons) on the gold surface. As a result, the energy
of photons is transferred to electrons, which convert into surface plasmons. Then, at a particular
angle (SPR angle) past the point of TIR, the momentum of photons in incident light matches the
momentum of the surface plasmons, leading to momentum resonance. This match enables a
resonant absorption of energy via the light-evanescent wave field, leading to a reflected light with
12

a minimum intensity (Figure 1.5). The amplitude of this evanescent field wave decreases
exponentially with increasing distance from the interface, which gives SPR a sensing depth of
around 200 nm, making it a surface-sensitive technique.

Figure 1.5 A simple schematic of SPR technique: a basic SPR instrument configuration (left); and
an example of SPR spectrum (right).

The SPR experiments are conventionally conducted by measuring reflectivity as a function of
incident angle under a fixed incident light wavelength. The minimum in reflectivity occurs at the
SPR angle, which varies with the refractive index of sensor surface as the molecules associate and
dissociate. And such SPR angle changes, as the interpretation of association and dissociation, are
recorded in real time as a graph called the sensorgram. SPR signal is usually expressed as
resonance units, RU, where 1000 RU equals to ~0.1° in SPR angle change. This scanning-angle
SPR approach is the most common SPR method and has been primarily commercialized by, for
example, Biacore company. 35 However, this approach is a single-channel measurement and
limited to be used in a high-throughput format.
The SPR imaging (SPRi) technique takes the SPR analysis a step further where it eliminates the
complexity of angle scanning while adds the benefits of array analysis. The SPRi experiments are
13

conducted at a fixed angle (just off of the SPR angle, Figure 1.6) of incidence, and the intensity of
reflected light from the metal surface is collected by a charge-coupled device (CCD) camera. Thus
the reflectivity is converted into pixel intensity in SPR images. When a change happens on the
sensor surface, the hypothetical SPR curve shifts and a change in pixel intensity of SPR images
should be observed. This design enables the CCD camera to visualize the whole of the array with
potentially hundreds of active spots on it. Thus potentially hundreds of interaction events such as
molecular binding, biomolecular interactions and kinetic processes can be investigated in parallel
within an array. And it is convenient to reserve certain SPRi spots of the array for positive and
negative controls so the complete information can be collected at the same time and under the
same condition as experimental samples.

Figure 1.6 SPR sensors using (A) scanning-angle SPR approach and (B) SPR imaging approach.
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1.3.2 SPR sensorgram
The first result from an SPR experiment, as presented in a real-time manner, is the sensorgram
(Figure 1.7). In the following section, the interaction between two molecules is taken as an example.
After forming a baseline, the analyte (A) is injected and an increasing SPR response can be
observed in the sensorgram as the analytes bind to the ligands (L) immobilized on the sensor
surface. If the analyte injection time is long enough, a steady-state response (often referred to as
equilibrium, Req) can be obtained. After all the analytes pass through the sensor surface, the SPR
response decreases as dissociation occurs. After this association-dissociation cycle completes,
regeneration solution is introduced to the sensor chip to remove any bound analyte and get ready
for the next analysis cycle.

Figure 1.7 An example of sensorgram showing the steps of an analysis cycle of association and
dissociation steps. The bars below the curve further explain every stage in the sensorgram.

From certain sensorgrams of interaction between the ligand and analyte, association rate constant
ka in M-1 s-1 and the dissociation rate constant kd in s-1can be deduced as described in following
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equations. Furthermore, the quotient of the kd/ka defines the equilibrium dissociation constant KD
in Molar. Equation 1 shows a reversible 1 to 1 interaction between the ligand (L) and analyte (A).

Equation 1.1

The association rate at association phase is expressed as SPR response Rt:
Equation 1.2
Where Rmax is the maximal SPR response when all the ligands are bound to analytes, and Req is:
Equation 1.3
While the dissociation rate at dissociation phase is expressed as:
Equation 1.4
where R0 is the SPR response at the start of the dissociation phase.

1.4 Liquid chromatography-mass spectrometry (LC-MS)
Liquid chromatography–mass spectrometry (LC-MS) combines LC and MS: LC separates the
components based on their different retention strength while MS ionizes and separates the
components based on their different mass-to-charge (m/z) ratio. 36,37 Such combination in this
analytical chemistry technique not only avoids the drawbacks of individual LC and MS technique
but also facilitate their advantages that separate the components twice, which is extremely helpful
for qualitative and quantitative analysis of complex components in a sample. As a result, it is
increasingly being employed in a wide range of fields, such as biotechnology, pharmaceuticals,
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environment monitoring, food processing, and cosmetic industries. In this dissertation, we used
LC-MS technique for protein and antibody determination.

1.4.1 Liquid Chromatography (LC)
In this dissertation, an ultra-high performance liquid chromatography UPLC system (Thermo
Scientific Dionex Ultimate 3000) was used for protein or peptide sample separation and delivery
for MS analysis. Currently, the (U)HPLC system is well standardized, which contains solvent
reservoir, pump(s), autosampler, column (and oven), and UV-Vis or MS detectors (Figure 1.8).36
The pump(s) delivers the solvent (mobile phase) from solvent reservoir to the system; the
autosampler inject samples into the system; components within the samples are separated inside
the column, and then analyzed by the detectors. The reversed-phase chromatography (RPC) is the
predominant (U)HPLC mode in use today, which was also used here. In general, RPC features a
nonpolar column in combination with a (polar) mixture of water plus an organic solvent as the
mobile phase. Currently, because of the explosive growth in proteomics, RPC separation of
proteins and peptides is a very mature technique with commercialized columns designed for
proteins or peptides and well-established (U)HPLC method.

Figure 1.8 A simple schematic of a modern (U)HPLC system
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1.4.2 Mass spectrometry (MS)
Mass spectrometry (MS) is a wide-ranging analytical technique in bioscience research.37
Essentially, it is an indispensable technology in protein analyses, including the abundance,
structures, modifications, functions, and inter or intra-molecular interactions of the target proteins.
The instrument used in MS is called mass spectrometer, which converts individual molecules into
charged molecules (ions) in the gas phase, then separates and measures these ions according to
their intrinsic mass-to-charge (m/z) ratio. The detailed analysis process constitutes the following
aspects: ions in the gas phase are first generated and introduced into the system with an ion source,
followed by separation in the mass analyzer based on their m/z ratios, and then the intensity of ions
is determined by the detector (Figure 1.9).

Figure 1.9 A simple schematic of a modern mass spectrometer

There are several ionization methods developed to generate and deliver the ions into the mass
analyzer(s), which include but are not limited to fast atom bombardment (FAB), electron impact
ionization (EI), chemical ionization (CI), electrospray ionization (ESI), atmospheric pressure
chemical ion ionization (APCI), and matrix-assisted laser desorption ionization (MALDI). ESI
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method has exhibited impressive capacities in analyzing large biomolecules (e.g., peptides,
proteins, carbohydrates, oligonucleotides) as it is a so-called “soft ionization” technique with very
little fragmentation of biomolecules in the ionization process.38,39 The second vital advantage of
ESI for large molecule analysis is that the large ions formed from ESI are usually multiply charged,
thus with the increased z, molecules of large molecular weight could still be investigated by the
mass analyzer with limited m/z ranges. The third advantage of ESI method is that such ionization
is an atmospheric process, making it compatible with LC. In this dissertation, all the MS-based
assays have been done by the ESI-based mass spectrometers.
The mass analyzer in the MS instrument separates ions based on m/z ratios and sends them to the
detector where they are converted to a digital output. The typical types of mass analyzers include
but are not limited to linear quadrupole (Q) analyzer, time of flight (TOF) analyzer, magnetic
sector analyzer, etc. In this dissertation, two kinds of mass analyzers were used, include linear
quadrupole analyzer (4000 QTRAP mass spectrometer, AB Sciex, and Thermo Scientific TSQ
Quantiva triple quadrupole mass spectrometer) and TOF analyzer (QSTAR Elite mass
spectrometer, AB Sciex). A linear quadrupole analyzer, as the name implies, typically consists
of four cylindrically shaped rod electrodes set parallel to each other. Ions travel through the
quadrupole between the rods. A radio frequency (RF) voltage with a direct current (DC) offset
voltage is applied to each opposing rod pair. By controlling the applied voltages, only selected
ions of an identical certain m/z ratio will reach the detector, while other ions will collide on the
rods. Thus, such linear quadrupole analyzer is more like an m/z filter. A TOF analyzer separates
ions based on the kinetic energy and velocity of the ions so the ions with different m/z ratio reach
the detector at different time (larger m/z, longer time). In detail, the ions first pass through an
electric field of known strength and obtain the same kinetic energy if they have the same z.
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However, their velocities are different as the velocity depends on the m/z ratio. The ions will then
“fly” over a known distance to reach a detector; the duration taken is measured and thus the m/z
ratio can be calculated based on this “time of flight” and other known experimental parameters.
The state-of-the-art TOF MS has a “reflectron” design to improve the resolving power (resolution)
of the mass analyzer In general, linear quadrupole analyzer is good at molecular quantification
while TOF analyzer is good at unknown molecule identification.
In the analytical practice, the precursor ions often travel though more than one analyzer (usually
two), which is as known as tandem MS (MS/MS, MS2, or even MSn). In such MS design (tandem
in space), two mass analyzers (usually first is Q, the second is either Q or TOF) are separated by a
collision cell (radio frequency collision quadrupole, q). The selected ions (precursor ions) by the
first mass analyzer (Q) enter into the collision cell and dissociation breaks the precursor ions to
smaller fragments (product ions). Various methods of ion dissociation are developed, which
include but are not limited to electron transfer dissociation (ETD), electron capture dissociation
(ECD), collision induced dissociation (CID), surface induced dissociation (SID), and higherenergy collisional dissociation (HCD). Among above methods, CID has been widely used and
heavily investigated in protein analyses. During the CID process, the precursor ions are accelerated
by electrical potential and gain high kinetic energy, then the ions collide with neutral molecules
(e.g., He, Ar, N2) in the collision cell (Figure 1.10, indicated as q2), therefore the kinetic energy is
converted into internal energy which causes bond breakage. The CID results in smaller fragments
(product ions), which can then be analyzed by the second mass analyzer. The tandem MS analyses
can interpret detailed structural information of large biomolecules such as sequencing peptides and
further profiling proteins as described in this dissertation using Q-TOF (or QqTOF) MS with
information dependent acquisition (IDA) method. Another use is setting two m/z selectors for
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selectively detecting the precursor ions with more sensitivity and specificity, as described in this
dissertation using QqQ (triple quadrupole) MS with multiple reaction monitoring (MRM) method.

Figure 1.10 Schematic MS analysis using (A) a quadrupole time-of-flight (Q-TOF) mass
spectrometer and (B) a triple quadrupole (QqQ) mass spectrometer
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Abstract
Peanut allergy can be life-threatening and is mediated by allergen-specific immunoglobulin E (IgE)
antibodies. Investigation of IgE antibody binding to distinct allergenic epitopes can more precisely
identify the specificity underlying the allergic responses. In this report, we describe a 45-min
surface plasmon resonance imaging (SPRi) immunoassay for differentiating IgE antibody
populations in an epitope-resolved fashion. IgE antibodies are first captured from 10 μL of serum
onto magnetic beads bearing IgE ε-chain specific antibodies. They are then introduced to an SPRi
array equipped with peptide and carbohydrate epitopes from the major peanut allergen
glycoprotein Arachis hypogaea h2 (Ara h2). For the first time, differential epitope responses were
achieved by providing a binding environment with conditions that minimized cross-reactivity
while maintaining high sensitivity. Excellent correlation was observed between IgE anti-Ara h2
by ImmunoCAP assay results and IgE binding to Ara h2-3 peptide epitope by SPRi results. A
weaker correlation was found between IgE anti-Ara h2 by ImmunoCAP assay results and IgE
binding to Ara h2-5 peptide and carbohydrate epitopes by SPRi results. These results provide
insights into the epitope specificity of peanut-specific human IgE antibodies and the role of
immunodominant epitopes and carbohydrates in allergy diagnosis. The analytical approach
described here is applicable to future microarrays featuring an expanded cohort of allergen
epitopes to achieve a more accurate fingerprint of a patient’s susceptibility and/or severity to
peanuts, or, in principle, any other allergens.
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2.1 Introduction
Food allergies are a major health concern worldwide, and its prevalence, particularly among
children, is on the rise.1-3 Peanut allergy is one of the most common food allergies, and the leading
cause of food allergy deaths.4 Exposure to even trace amounts of materials derived from peanuts
can induce a serious reaction (e.g., anaphylactic shock) to a sensitized individual who is allergic
to peanut storage proteins. Treatment requires an immediate epinephrine shot followed by a visit
to the emergency room. Thus, there is a persistent and critical need for improved diagnostic
methods that can accurately predict a patient’s severity of allergic reactions to peanuts.
While the gold standard method in diagnosis of peanut allergy is the double-blind, placebocontrolled food challenge (DBPCFC), this technique is expensive, time consuming, and potentially
dangerous. The current state-of-the-art procedure is to perform a clinical history and then confirm
sensitization with a serological assay aiming at peanut specific IgE antibodies. Such assay is a
widely employed diagnostic IgE antibody assay with a name of ImmunoCAP, and it uses
allergosorbents where both peanut extract and a number of individual allergenic peanut (Arachis
hypogaea) proteins (Ara h1, 2, 3, 8, and 9) are immobilized.5,6 Several studies have shown that the
presence and amounts of IgE antibodies specific for the major peanut storage proteins (e.g., Ara
h1, 2, and 3; especially Ara h2) are particularly helpful in confirming a clinically relevant
sensitization and predicting the relative severity of a peanut allergic reaction.7,8
Higher resolution information about specific peptide sequences (or epitopes) of Ara h2 recognized
by IgE antibodies has been obtained using peptide array methods. 9 - 11 In these studies, IgE
antibodies bind to the peptides with overlapping sequences selectively and differentially based on
the epitopes that are recognized. Certain regions of a protein, therefore, are inherently more
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immunogenic than others if more antibodies bind to them. Thus, the properties of the IgE repertoire
logically have a direct impact on the degree of allergic reactions that an individual will experience.
Parameters such as total IgE antibody concentration, the diversity of epitopes recognized, the
affinity of the IgE antibodies for those epitopes, and the ratio of allergen specific IgE to total IgE
are the most important in this regard.12 A model where tight binding by IgE at one site, when in
proximity to at least one other lower affinity IgE site, is sufficient to induce degranulation, a key
process that if sufficiently massive can lead to anaphylaxis.13,14 (Figure 1.4 in Chapter 1) Our long
term goal is to elucidate how IgE antibody concentration and affinity contribute allergic reactions
in an epitope resolved manner. This will allow for fundamental investigation of the link between
IgE antibody repertoire as measured in serum and objective clinical manifestation of the allergic
reactions. It may also provide information about the severity of the allergic reactions. Here we
focus on the differential recognition of Ara h2 epitopes by IgE antibodies using surface plasmon
resonance imaging (SPRi).
We previously reported the use of an Ara h2 peptide as a defined epitope to sense a peanut-specific
chicken IgY antibody by electrochemical impedance spectroscopy15 and resistive-pulse sensing16.
More recently, we reported our first microfluidic immunoarray for IgE antibodies utilizing both
peptide and carbohydrate epitopes. However, the measured concentrations of IgE antibodies that
bound to each epitope were statistically indistinguishable.17 In this study, we have modified the
experimental conditions to improve IgE antibody binding selectivity to different epitopes. So
herein, we present a simple method that is able to differentiate IgE antibody populations in an
epitope resolved manner using superparamagnetic particles (MP), a commercial SPRi array system,
and an off-line IgE capture strategy (Scheme 2.1). Secondary antibodies (Ab2) specific to ε-chain
of human IgE antibodies were immobilized onto the MPs to bind IgE antibodies from human serum.
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This tended to lower the non-specific binding of other serum proteins to SPRi array surface.18-20
Differential epitope responses to allergen specific IgE antibodies were obtained by providing a
binding environment designed to detect low IgE antibody concentrations with minimal crossreactivity. Using this approach, IgE antibodies from peanut sensitized patient sera were
distinguishable in terms of binding to each of the Ara h2 epitopes and they correlated well with
ImmunoCAP assays using Ara h2 allergosorbent. Statistical analysis of our limited patient sample
data shows good peanut allergy diagnostic potential and provides epitope specific immunogenic
information that can be correlated with IgE-mediated allergic reactions.

Scheme 2.1 Schematic for detection of epitope specific IgE antibodies using SPRi. IgE antibodies
were first captured by MP-Ab2, washed, and injected into an SPRi array; SPRi responses were then
measured on individual array spot that has been immobilized with specific allergenic epitopes.
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2.2 Experimental
2.2.1 Chemicals and materials
Two Ara h2 derived 17-mer peptides (Ara h2-3, Ac-ERDPYSPSQDPYSPSQK-amide, 2022.2 Da;
and Ara h2-5, Ac-QQEQQFKRELRNLPQQK-amide, 2239.6 Da) were synthesized by AnaSpec,
Inc. The glycosides with butylamine linker, α(1,3)-fucosyl glycoside (AFG) and β(1,2)-xylosyl
glycoside (BXG), were synthesized as reported17,21. Monoclonal anti-human IgE (anti-IgE) and
bovine serum albumin (BSA) was from Sigma-Aldrich. Biotinylated polyclonal ε-chain specific
anti-human IgE (Ab2) was from Vector Laboratories. Human IgE antibody mixture (clone HE1)
and streptavidin coated superparamagnetic particles (Dynabeads MyOne Streptavidin T1) were
from Thermo Fisher Scientific. Antibody pairs (capture and detection antibodies) and cancer
biomarker protein standards were from DuoSets of prostate-specific antigen (PSA), insulin-like
growth factor 1 (IGF-1), vascular endothelial growth factor D (VEGF-D), and cluster of
differentiation 14 (CD14), provided by R&D Systems, Inc. The monothiolalkane(C11)PEG3-OH
and monothiolalkane(C11)PEG6-COOH were purchased from SensoPath Technologies, Inc. The
SpotReady™ 25 arrays for SPRi measurements were from GWC technologies. Other chemicals
and materials were all from Sigma-Aldrich unless otherwise noted. All solutions were prepared
using 18 MΩ cm water purified by passing through a Hydro Service and Supplies purification
system. The running buffer in SPRi experiments is 10 mM phosphate-buffered saline containing
0.05% Tween 20 (PBS-T, pH 7.4), which was made freshly, passed through a 0.22 µm filter, and
degassed in a vacuum chamber before use.
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Thirty two coded sera from peanut sensitized patients were provided from the serum bank at the
Johns Hopkins University Dermatology, Allergy and Clinical Immunology (DACI) Reference
Laboratory.

2.2.2 General SPRi procedures and instrumentation
SPRi measurements were performed using GWC SPR imager II (GWC technologies, WI, USA)
coupled with a microfluidics syringe pump (Model No. NE4002X, New Era Pump Systems, Inc.)
and a Rheodyne chromatographic injector employing 100 μL sample loop (Product No. 9725i,
IDEX Health & Science LLC.) to deliver samples to the array at a controlled flow rate.
The sensor array was prepared by individually spotting different epitopes onto 25 gold spots of
one SpotReady™ 25 SPRi array (GWC Technologies). In brief, the array was first immersed in
ethanol solution of monothiol alkane PEG6-COOH and monothiol alkane PEG3-OH (1:9 ratio, 2
mM total concentration) for 12 h. The functionalized array was then activated using aqueous
solution containing 400 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 100
mM N-hydroxysulfosuccinimide (NHSS) for 10 min, followed by coupling amine groups of antiIgE, peptides, carbohydrates, and BSA onto different spots at room temperature in a humidified
chamber. After 3 h, the SPRi array, a 3D-printed serpentine flow channel piece (Figure 2.1), a
prism and the flow cell assembly components were immediately assembled and connected to the
pump and injector using PEEK tubing. Before analyses, 1 M ethanolamine (pH 8.5) were
introduced onto the spots to quench the EDC/NHSS derivatives for 10 min, followed by 5 min
equilibrium with PBS-T as running buffer. The incident light angle was then tuned and fixed to a
position to one third of the difference between the minimum and maximum reflectivities.22 All
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binding events were recorded in real-time using digital optics V++ software which converts pixel
intensity values from each spot and then plots these values against time simultaneously. After each
run, the SPRi array was regenerated using 60 s pulse of 10 mM NaOH at 100 μL min-1,23 which
gave a better reproducibility of surface regeneration than either 10 or 100 mM HCl. The SPR
image (in TIF format) recorded before binding event is subtracted from that after binding to obtain
the SPR difference image and later processed using ImageJ software form NIH (Figure 2.3A).24

2.2.3 3D-printed channel piece
The microfluidic flow channel for SPRi SpotReady™ 25 arrays is unavailable from the
manufacturer, thus a serpentine channel piece was designed and fabricated using Formlabs Form
2 SLA 3D Printer (Formlabs, Inc.). Computer aided design of serpentine channel was created using
123 design software from Autodesk. The channel pieces were then 3D-printed using acrylate based
flexible resin, followed by UV post cure (Figure 2.1). Two holes, as inlet and outlet, were made
by a needle. The channel piece was then sonicated in isopropanol for 20 min and thoroughly
washed by water. Before assembled with SPRi array, the channel piece was immersed in PBS-T
buffer containing 0.1% BSA for 30 min to block the channel surface. After assembled, the
microfluidic channel covered all sensing spots and no leakage happened during entire assays. The
volume of channel is around 10 μL, and the channel piece is reusable for at least dozens of times.
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Figure 2.1 (A) 3D-printed flow channel piece featuring serpentine groves; (B) Flow of green
solution through the microfluidic channels when the channel piece is assembled with SPRi array
and prism for SPRi measurements; (C) A real raw SPR image showing the channel covers all the
sensing spots. The spot at bottom right corner is for orientation purpose; it is not the sensing spot.

2.2.4 Synthesis of MP-Ab2 bioconjugates
Biotinylated polyclonal ε-chain specific anti-human IgE antibodies produced in goat (Ab2) were
conjugated to 1 μm diameter streptavidin coated MPs following protocol supplied by the
manufacturer. Briefly, 40 μL of streptavidin coated MP (10 mg mL-1) was washed three times with
10 mM PBS, pH 7.4 containing 0.1% BSA, and finally reconstituted in 390 μL of 0.1% BSA in
PBS. Then 10 μL of biotinylated Ab2 was added to MP dispersion and mixed in 1.5 mL
microcentrifuge tube at 37°C for 30 min with slow tilt rotation. Thus formed MP-Ab2
bioconjugates via biotin-streptavidin interaction were magnetically separated using Invitrogen
DynaMag™- Spin Magnet, washed three times with PBS-T buffer to remove unbound Ab2, and
reconstituted with 400 μL PBS-T to make a stock dispersion of MP-Ab2 bioconjugates.
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2.2.5 Detection of IgE antibodies using offline capture on MP-Ab2 bioconjugates
The MP-Ab2 bioconjugates were used to capture IgE antibodies reconstituted in 100 fold dilution
of calf serum. Briefly, 30 μL stock dispersion of MP-Ab2 bioconjugates and 30 μL IgE from dilute
serum was mixed with 240 μL PBS-T for 30 min at 37°C with continuous mixing under tilt rotation.
The MP-Ab2 bioconjugates with captured IgEs were magnetically separated, washed three times
with PBS-T, and reconstituted in 300 μL of PBS-T. Thus formed MP-Ab2-IgE conjugates were
then injected into the SPRi array at 10 μL min-1 with the real-time SPRi monitoring.

2.3 Results
2.3.1 The amount of Ab2 molecules on MP-Ab2 bioconjugates
The amount of Ab2 on MP-Ab2 bioconjugates were estimated using anti-goat IgG (whole
molecule)-FITC antibody produced in rabbit (AntiAb2FITC). In brief, a series of MP-Ab2
bioconjugates were prepared using 10 μL biotinylated Ab2 of different concentrations, followed
by mixing with AntiAb2FITC at room temperature for 1 h with slow tilt rotation. The amount of
AntiAb2FITC used was at least ten-fold that of Ab2 used in MP-Ab2 preparation to make sure
sufficient binding. Thus formed bioconjugates (MP-Ab2-AntiAb2FITC) were magnetically
separated, again washed three times with PBS-T, and reconstituted in 150 μL PBS-T. Fluorescence
emission spectra of the AntiAb2FITC itself and the MP-Ab2-AntiAb2FITC bioconjugates were
immediately measured under 495 nm excitation wavelength using FlexStation 3 Multi-Mode
Microplate Reader (Molecular Devices, LLC.). The emission spectra had a maximum at 525 nm
(Figure 2.2A), which is proportional to the amount of AntiAb2FITC (Figure 2.2B). Using the
calibration in Figure 2.2B and assuming 1:1 binding ratio between Ab2 and AntiAb2FITC, the
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fluorescence intensities of MP-Ab2-AntiAb2FITC bioconjugates (Figure 2.2C) were converted to
the number of Ab2 per particle (other assumptions include molecular weight of AntiAb2FITC
antibodies is ~150 kDa and 1 mg MP is corresponding to 8.5 × 108 particles according to the
manufacturer), and around 60,000 Ab2 molecules were estimated on one MP-Ab2 bioconjugate if
50 μg mL-1 Ab2 were used in MP-Ab2 preparation step (Figure 2.2).

Figure 2.2 (A) Fluorescence emission spectra of AntiAb2FITC under excitation of 495 nm. (B)
Calibration plotting between relative fluorescence intensities of AntiAb2FITC and its
concentrations. (C) Fluorescence emission spectra of MP-Ab2-AntiAb2FITC bioconjugates under
excitation of 495 nm. (D) Plotting between relative fluorescence intensities of bioconjugates in (C)
and Ab2 concentrations in MP-Ab2 preparation step. Around 60,000 Ab2 molecules were estimated
on one MP-Ab2 bioconjugate if 50 μg mL-1 Ab2 was used.
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2.3.2 Detection of IgE antibodies using offline capture on MP-Ab2 bioconjugates
SPR images were collected in real time for the whole array. The brightness of spots in the SPR
difference image indicated the specific binding of MP-Ab2-IgE complexes onto those spots (Figure
2.3A): anti-IgE shows the highest amount of binding to human IgE, followed by carbohydrates
(AFG and BXG) and then peptides (Ara h2-3 and Ara h2-5); BSA shows almost no human IgE
binding. Meanwhile, the image pixel intensities were plotted as SPRi responses against time,
generating sensorgrams that were used for quantitative analysis (Figure 2.3B). SPRi response does
not decrease after switching to buffer (PBS-T washing), suggesting very low dissociation constant
values of MP-Ab2-IgE bioconjugates on the spot.25 After using 60 s pulse of 10 mM NaOH at 100
μL min-1, the SPRi responses were back to baseline (regeneration).

Figure 2.3 SPRi of human IgE binding to peptides, carbohydrates, and anti-IgE spots. (A)
Recolorized SPR difference image for 100 pg mL-1 human IgE in 100 fold diluted calf serum.
Spots decorated by different detection probes are highlighted within the yellow boxes. (B) Raw
real-time SPRi response curves (sensorgrams) recorded on an anti-IgE spot (red) and a BSA spot
(black) during sensing100 pg mL-1 human IgE. μRIU: micro-Refractive Index Unit.
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2.3.3 Optimization of experiment conditions
To establish optimal conditions for the assays, i.e., to differentiate epitopes to IgE responses and
to improve on both the signal to noise ratio and sensitivity, we optimized epitope surface coverage
and flow rate. As seen in Figure 2.4, significant differentiation of IgE binding response was
achieved when epitope concentrations used to coat the array were 0.1 mg mL-1 for peptides and
0.2 mg mL-1 for carbohydrates. In addition, flow rate was optimized (Figure 2.5). The flow rate of
5 μL min-1 gave the highest SPRi response on Anti-IgE spot, but the response on BSA spot was
also high, probably due to the non-specific binding or sedimentation of MP. Compare flow rates
of 10 and 20 μL min-1, the former one gave a higher SPRi response on Anti-IgE spot while the
response on BSA spot was comparable to the latter. Thus, flow rate of 10 μL min-1 was used to
generate the sufficient SPRi response while minimizing the non-specific binding. These conditions
were subsequently used to prepare arrays and develop assay calibrations using offline capture of
IgE antibodies from serum.
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Figure 2.4 SPRi signals generated on anti-IgE, Ara h2-3, Ara h2-5, AFG, and BXG coated spots
with varying concentrations of epitopes using off-line capture for detection of IgEs in 100 fold
diluted calf serum. Significant differentiation of IgE binding responses was achieved when epitope
concentrations used to coat the array were 0.1 mg mL-1 for peptides and 0.2 mg mL-1 for
carbohydrates. μRIU: micro-Refractive Index Unit.

Figure 2.5 Optimization of flow rate for IgE detection: (A) 5 μL min-1; (B) 10 μL min-1; (C) 20
μL min-1. The dash lines indicate switching back to PBS-T buffer. μRIU: micro-Refractive Index
Unit.
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2.3.4 Calibration assays
Different concentrations of a human IgE antibody standard (Thermo Fisher) diluted in calf serum
were analyzed to create dose response curves (Figure 2.6). Limits of detection (LoD) for IgE
antibody were 0.5 pg mL-1 on anti-IgE spots, 5.0 pg mL-1 on peptide spots, and 2.0 pg mL-1 on
carbohydrate spots, all of which were over 50-fold better than LoD of ImmunoCAP assay. The
analytical sensitivity as defined by the slope of calibration curve on anti-IgE spots differed
significantly from those on peptide and carbohydrate spots according to t-test (P < 0.01). The
dynamic ranges of calibration plots were over two orders of magnitude for all the epitope spots.
These results illustrate the potential of the SPRi to differentiate epitope specific IgE antibodies in
patient samples.

Figure 2.6 Calibration assays for human IgE antibodies spiked in calf serum: (A) background
subtracted SPRi responses for IgE antibodies captured on MP-Ab2 and injected to anti-IgE
immobilized SPRi spots; (B~F) calibration plots of human IgE antibodies measured in calf serum
on SPRi spots coated with (B) anti-IgE, (C) Ara h2-3, (D) Ara h2-5, (E) AFG, and (F) BXG. Error
bars represent standard deviations for n = 4. μRIU: micro-Refractive Index Unit.
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2.3.5 Specificity assay by detecting cancer biomarker proteins
The specificity of our platform was examined using four cancer biomarker proteins including
prostate-specific antigen (PSA), insulin-like growth factor 1 (IGF-1), vascular endothelial growth
factor D (VEGF-D), and cluster of differentiation 14 (CD14), all of which normal serum levels are
comparable to normal IgE levels. Similar to IgE detection, those biomarkers were first dissolved
in calf serum, further captured by corresponding MP-Ab2 bioconjugates (here Ab2 is their own
detection antibody), washed and reconstituted in running buffer, followed by flowing though SPRi
spots coated with anti-IgE, Ara h2-3, Ara h2-5, AFG, BXG and their own capture antibody.

Figure 2.7 Specific study for sensing four common cancer biomarker proteins (A) PSA; (B)
VEGF-D; (C) IGF-1; (D) CD 14. SPRi responses were collected on spots coated with anti-IgE,
Ara h2-3, Ara h2-5, AFG, BXG and their own capture antibodies, respectively. μRIU: microRefractive Index Unit.
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No significant SPRi response was found on spots coated by peanut protein epitopes or anti-IgE
antibody, analyzed via t-test comparing with the SPRi responses obtained on their own capture
antibodies (Figure 2.7).

2.3.6 Statistical analysis of patient sample data
Thirty two coded sera from peanut sensitized patients were from the serum bank at the Johns
Hopkins University DACI Reference Laboratory. Statistical analyses (t-test and ROC analysis)
were performed using MedCalc for Windows, version 17.6 (MedCalc Software, Ostend, Belgium).
The sera were analyzed in the SPRi array after a 100~10,000 fold dilution to bring their SPRi
responses into the linear range of the assay. The measured concentrations in ng mL-1 were
converted to kU L-1 (1 kU L-1 = 2.42 ng mL-1)26 and further compared with the ImmunoCAP assays.
The ImmunoCAP results provided the IgE antibody levels against whole peanut extract and
individual Ara h1, 2, 3, 8, and 9 proteins in a range from 0.1 to 100 kU L-1. The outlier values were
reported as < 0.1 kU L-1 or > 100 kU L-1, but plotted as 0.1 kU L-1 and 100 kU L-1, respectively.
The historical threshold 0.35 kU L-1 was used as a cutoff for positive and negative results.27 As
IgE antibodies specific for Ara h2 is considered by many to be the most accurate predictor of a
risk for a severe reaction in peanut sensitized individuals, two groups were categorized based on
having negative (n = 13) and positive (n = 19) results in levels of IgE anti-Ara h2 (Figure 2.8).
Significant differences in level of IgE anti-Ara h2-3 peptide epitope were observed between those
two groups (Figure 2.8B) and confirmed by t-test (P < 0.01, Table 2.1). On the other hand,
measured IgE antibody levels between negative and positive groups when using array spots
containing peptide epitope Ara h2-5, the two carbohydrate epitopes, or anti-IgE antibody (Figure
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2.8C~F) were found statistically indistinguishable by t-test (P > 0.01, Table 2.1). These results
confirm that our new immunoassay strategy resulted in differentiation of IgE antibody binding to
each epitope.

Figure 2.8 Distributions of IgE antibody levels in individuals having negative (n = 13) and positive
(n = 19) levels of IgE anti-Ara h2 (IgEaArah2): IgE antibodies against (A) Ara h2; (B) Ara h2-3;
(C) Ara h2-5; (D) AFG; (E) BXG; (F) Anti-IgE.

Table 2.1 The P values by independent t-tests in levels of IgE antibodies specific for four Ara h2
epitopes and anti-IgE, between two groups having negative and positive levels of IgE anti-Ara h2.
The MedCalc software generated P values, which can be compared with significance level (0.01)
to determine whether two groups have statistically significant differences.
t-test in level of IgE
antibodies against

Anti-IgE

Ara h2-3

Ara h2-5

AFG

BXG

P value

0.1676

0.0067

0.0754

0.5741

0.7098
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Receiver operating characteristic (ROC) analyses 28 were used to examine the ability of each
epitope to confirm sensitization to peanuts. In ROC, the true positive rate (sensitivity) is plotted
against false positive rate (1-specificity) at various cutoff levels. A perfect diagnostic tool should
achieve 100% sensitivity and 100% specificity, of which ROC curve passes through point (0, 1).
Therefore the closer the curve is to point (0, 1), the higher the overall accuracy of the prediction
method. A more quantitative way to judge the accuracy of the prediction method is to compare the
area under the curve (AUC), and similarly the closer to 1, the more accurate. ROC curves for levels
of IgE antibodies against four Ara h2 epitopes and anti-IgE are shown in Figure 2.9. The IgE antiAra h2-3 exhibited the best prediction for sensitization with the area under the curve (AUC) of
0.85, 73.7% sensitivity and 100.0% specificity (Table 2.2).

Figure 2.9 The receiver operating characteristic (ROC) curves for peanut sensitization
confirmation using levels of IgE antibodies against four peanut epitopes and anti-IgE.
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Table 2.2 The area under the curve (AUC), sensitivity, and specificity for peanut sensitization
confirmation by the receiver operating characteristic (ROC) analysis.

Anti-IgE
Ara h2-3
Ara h2-5
AFG
BXG

AUC

sensitivity,%

specificity,%

0.64 ± 0.11
0.85 ± 0.07
0.68 ± 0.10
0.51 ± 0.12
0.567 ± 0.11

79.0
73.7
84.2
100.0
52.6

53.9
100.0
53.9
53.9
69.2

2.4 Discussion
Our epitope resolved analytical system depends on minimizing cross-reactivity while maintaining
high analytical sensitivity. Its ability to measure IgE levels in the pg mL-1 range with relatively
low epitope surface coverage minimizes the cross-reactivity of other IgE antibody specificities.
Using MP enables the SPRi to detect pg mL-1 levels of IgE antibodies by increasing both the
refractive index of the binding moiety and the apparent binding constant of IgE antibody. Around
60,000 Ab2 molecules were estimated on one MP-Ab2 bioconjugate (Figure 2.2), which facilitates
efficient IgE capture by driving the Ab2 + IgE

[Ab2ꞏIgE] equilibrium toward association.

Using the off-line capture approach, IgE antibodies were separated from non-specific serum
proteins, resulting in a higher analytical sensitivity and a clearer signal differentiation with each
epitope. Importantly, this capture strategy rules out the binding of other anti-peanut antibodies (e.g.
IgG4) to Ara h2 epitopes.9
Since Ara h2-specific IgE antibody levels are important in the evaluation of a patient for peanut
allergy, two peptides bearing Ara h2 anti-peanut IgE binding epitopes were evaluated in this study
(Ara h2-3 and Ara h2-5). The IgE antibodies specific for Ara h2-3 provide an enhanced correlation
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for sensitization to peanuts than those for Ara h2-5 epitope (Figure 2.8 and 2.9, Table 2.1 and 2.2).
It indicates that Ara h2-3 is a more prominent epitope of the Ara h2 protein. These data agree with
other epitope mapping studies.9-11 Such differences in IgE antibody levels might result from their
different positions and secondary structures in the Ara h2 protein (Figure 2.10)29: Ara h2-3 presents
a protruding, flexible surface loop, which is easily accessible for IgE binding in allergic reactions,
while Ara h2-5 maintains a rigid α-helix structure that is buried behind Ara h2-3 in Ara h2 protein.
Thus most Ara h2-specific IgE antibodies may bind to the immunodominant epitope of Ara h2-3
rather than Ara h2-5.

Figure 2.10 The 3D structure of the major peanut allergen protein Ara h2 (obtained from The
Protein Data Bank, PDB entry 3OB4).29 The epitope Ara h2-3 and Ara h2-5 are highlighted in red
and blue color, respectively, to indicate their position and secondary structure, using The PyMOL
Molecular Graphics System, Version 1.8 Schrödinger, LLC. Some residues connecting Ara h2-3
are missing in the crystal structure PDB 3OB4.

In addition, two carbohydrate epitopes (AFG and BXG) were investigated to examine the effect
of cross-reactive carbohydrate determinants (CCDs), as xylose and core-3-linked fucose residues
from CCDs can also contribute to peanut specific IgE antibody binding.30,31 The presence of these
sugars on glycoproteins from numerous plant species is thought to be responsible for sensitization
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profiles due to cross-reactivity. Our results indicate that the level of IgE specific for AFG or BXG
gave a poor correlation with sensitization profiles from the ImmunoCAP using either t-test or ROC
analysis (Figure 2.8 and 2.9, Table 2.1 and 2.2). Our findings, together with others32, question the
relevance of CCDs in the allergic response.33,34
A model initially proposed by Aalberse et al.13 and later demonstrated experimentally by
Christensen et al.14 is likely operative in our system. In this model, an allergen is initially captured
by one IgE antibody anchored on the mast cell surface followed by binding to another IgE in closeproximity (Figure 1.4 in Chapter 1). Similarly, in the SPRi assay, IgE antibodies are first anchored
onto MP-Ab2, whose size is comparable to a cell. The IgE antibody is then allowed to interact with
epitopes on the array spots. Throughout the assay, the flow rate creates a dynamic, non-static
condition, similar to the circulatory system. The pg mL-1 levels of IgE antibody that can be
measured with relatively low epitope surface coverage reflect the fact that only a subset of
circulating allergen proteins can interact with IgEs and trigger the immune response.35

2.5 Conclusions
In summary, we describe an epitope resolved assay system for the detection of peanut allergen
specific IgE antibodies using SPRi technology. The assay achieves LODs of 0.5~5.0 pg mL-1 using
MP and produces differential IgE responses to different Ara h2 epitopes. The SPRi array results
correlate well with ImmunoCAP results from repository based sera and provide insights into the
molecular epitopes involved in sensitization to peanuts. This analytical approach is applicable to
future microarrays that employ an expanded cohort of allergen epitopes to achieve a clear
fingerprint of a patient’s sensitization profile and risk for a severe reaction to peanuts.
45

2.6 References
1

S. H. Sicherer, H. A. Sampson, Food allergy, J. Allergy Clin. Immunol. 2010, 125, S116−S125.

2

S. H. Sicherer, A. Muñoz-Furlong, J. H. Godbold, H. A. Sampson, US prevalence of self-reported
peanut, tree nut, and sesame allergy: 11-year follow-up, J. Allergy Clin. Immunol. 2010, 125,
1322−1326.
3

S. Bunyavanich, S. L. Rifas-Shiman, T. A. E. Platts-Mills, L. Workman, J. E. Sordillo, M. W.
Gillman, D. R. Gold, A. A. Litonjua, Peanut allergy prevalence among school-age children in a
US cohort not selected for any disease, J. Allergy Clin. Immunol. 2014, 134, 753−755.
4

S. A. Bock, A. Muñoz-Furlong, H. A. Sampson, Further fatalities caused by anaphylactic
reactions to food, 2001-2006, J. Allergy Clin. Immunol. 2007, 119, 1016−1018.

5

K. J. De Knop, C. H. Bridts, M. M. Verweij, M. M. Hagendorens, L. S. De Clerck, W. J. Stevens,
D. G. Ebo, Component-resolved allergy diagnosis by microarray: potential, pitfalls, and prospects,
Adv. Clin. Chem. 2010, 50, 87−101.
6

N. Nicolaou, M. Poorafshar, C. Murray, A. Simpson, H. Winell, G. Kerry, A. Härlin, A.
Woodcock, S. Ahlstedt, A. Custovic, Allergy or tolerance in children sensitized to peanut:
prevalence and differentiation using component-resolved diagnostics, J. Allergy Clin. Immunol.
2010, 125, 191−197.
7

M. Ebisawa, R. Movérare, S. Sato, N. Maruyama, M. P. Borres, T. Komata, Measurement of ara
h 1-, 2-, and 3-specific ige antibodies is useful in diagnosis of peanut allergy in japanese children,
Pediatr. Allergy Immunol. 2012, 23, 573−581.
8

Y. Zhuang, S. C. Dreskin, Redefining the major peanut allergens, Immunol. Res. 2013, 55,
125−134.
9

W. G. Shreffler, D. A. Lencer, L. Bardina, H. A. Sampson, IgE and IgG4 epitope mapping by
microarray immunoassay reveals the diversity of immune response to the peanut allergen, Ara h
2, J. Allergy Clin. Immunol. 2005, 116, 893−899.
10

K. Otsu, R. Guo, S. C. Dreskin, Epitope analysis of Ara h 2 and Ara h 6: Characteristic patterns
of IgE-binding fingerprints among individuals with similar clinical histories, Clin. Exp. Allergy
2015, 45, 471−484.

11

Y. Han, J. Lin, L. Bardina, G. A. Grishina, C. Lee, W. H. Seo, H. A. Sampson, What
characteristics confer proteins the ability to induce allergic responses? IgE epitope mapping and
comparison of the structure of soybean 2S albumins and Ara h 2, Molecules 2016, 21, 1−11.
12

R. G. Hamilton, D. W. MacGlashan, S. S. Saini, IgE antibody-specific activity in human allergic
disease, Immunol. Res. 2010, 47, 273−284.

13

R. C. Aalberse, I. K. Budde, S. O. Stapel, R. van Ree, Structural aspects of cross-reactivity and
its relation to antibody affinity, Allergy 2001, 56, 27−29.

46

14

L. H. Christensen, J. Holm, G. Lund, E. Riise, K. Lund, Several distinct properties of the IgE
repertoire determine effector cell degranulation in response to allergen challenge, J. Allergy Clin.
Immunol. 2008, 122, 298−304.

15

H. Liu, R. Malhotra, M. W. Peczuh, J. F. Rusling, Electrochemical immunosensors for
antibodies to peanut allergen Ara h2 using gold nanoparticle-peptide films, Anal. Chem. 2010, 82,
5865−5871.

16

Y. Wang, K. Kececi, M. V. Mirkin, V. Mani, N. Sardesai, J. F. Rusling, Resistive-pulse
measurements with nanopipettes: detection of Au nanoparticles and nanoparticle-bound antipeanut IgY, Chem. Sci. 2013, 4, 655−663.

17

A. A. Joshi, M. W. Peczuh, C. V Kumar, J. F. Rusling, Ultrasensitive carbohydrate-peptide SPR
imaging microarray for diagnosing IgE mediated peanut allergy, Analyst 2014, 139, 5728−5733.
18

S. Krishnan, V. Mani, D. Wasalathanthri, C. V. Kumar, J. F. Rusling, Attomolar detection of a
cancer biomarker protein in serum by surface plasmon resonance using superparamagnetic particle
labels, Angew. Chem. Int. Ed. 2011, 50, 1175−1178.
19

V. Singh, C. Rodenbaugh, S. Krishnan, Magnetic optical microarray imager for diagnosing type
of diabetes in clinical blood serum samples, ACS Sensors 2016, 1, 437−443.

20

V. Singh, R. Nerimetla, M. Yang, S. Krishnan, Magnetite-quantum dot immunoarray for
plasmon-coupled-fluorescence imaging of blood insulin and glycated hemoglobin, ACS Sensors
2017, 2, 909−915.
21

M. Shen, A. A. Joshi, R. Vannam, C. K. Dixit, R. G. Hamilton, C. V Kumar, J. F. Rusling, M.
W. Peczuh, Epitope-resolved detection of peanut-specific IgE antibodies by surface plasmon
resonance imaging, ChemBioChem 2018, 19, 199–202

22

T. T. Goodrich, A. W. Wark, R. M. Corn, H. J. Lee, Surface plasmon resonance imaging
measurements of protein interactions with biopolymer microarrays in New Emerg. Proteomic
Tech., (Eds.: D. Nedelkov, R. Nelson), Humana Press, New Jersey, 2006, pp. 113−130.
23

Y. Wang, J. Dostalek, W. Knoll, Magnetic nanoparticle-enhanced biosensor based on gratingcoupled surface plasmon resonance, Anal. Chem. 2011, 83, 6202−6207.

24

C. A. Schneider, W. S. Rasband, K. W. Eliceiri, NIH Image to ImageJ: 25 years of image
analysis, Nat. Methods 2012, 9, 671−675.

25

V. Mani, D. P. Wasalathanthri, A. A. Joshi, C. V. Kumar, J. F. Rusling, Highly efficient binding
of paramagnetic beads bioconjugated with 100 000 or more antibodies to protein-coated surfaces,
Anal. Chem. 2012, 84, 10485−10491.
26

M. Bazaral, R. N. Hamburger, Standardization and stability of immunoglobulin E (IgE), J.
Allergy Clin. Immunol. 1972, 49, 189−191.

27

R. I. Siles, F. H. Hsieh, Allergy blood testing: A practical guide for clinicians, Cleve. Clin. J.
Med. 2011, 78, 585−592.
28

M. H. Zweig, G. Campbell, Receiver-operating characteristic (ROC) plots: A fundamental
evaluation tool in clinical medicine, Clin. Chem. 1993, 39, 561−577.
47

29

G. A. Mueller, R. A. Gosavi, A. Pomés, S. Wünschmann, A. F. Moon, R. E. London, L. C.
Pedersen, Ara h 2: crystal structure and IgE binding distinguish two subpopulations of peanut
allergic patients by epitope diversity, Allergy 2011, 66, 878−885.
30

R. van Ree, M. Cabanes-Macheteau, J. Akkerdaas, J. P. Milazzo, C. Loutelier-Bourhis, C.
Rayon, M. Villalba, S. Koppelman, R. Aalberse, R. Rodriguez, L. Faye, P. Lerouge, β(1,2)-xylose
and α(1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens, J.
Biol. Chem. 2000, 275, 11451−11458.
31

S. P. Commins, Carbohydrates as allergens, Curr. Allergy Asthma Rep. 2015, 15, 492.

32

F. Holzweber, E. Svehla, W. Fellner, T. Dalik, S. Stubler, W. Hemmer, F. Altmann, Allergy
2013, 68, 1269−1277.
33

H. Malandain, Inhibition of IgE binding to cross-reactive carbohydrate determinants enhances
diagnostic selectivity, Eur. Ann. Allergy Clin. Immunol. 2005, 37, 122−128.

34

S. P. Commins, T. A. E. Platts-Mills, Allergenicity of carbohydrates and their role in
anaphylactic events, J. Allergy Clin. Immunol. 2009, 124, 652−657.
35

C. Lupinek, E. Wollmann, A. Baar, S. Banerjee, H. Breiteneder, B. M. Broecker, M. Bublin, M.
Curin, S. Flicker, T. Garmatiuk, H. Hochwallner, I. Mittermann, S. Pahr, Y. Resch, K. H. Roux,
B. Srinivasan, S. Stentzel, S. Vrtala, L. N. Willison, M. Wickman, K. C. Lødrup-Carlsen, J. M.
Antó, J. Bousquet, C. Bachert, D. Ebner, T. Schlederer, C. Harwanegg, R. Valenta, Advances in
allergen-microarray technology for diagnosis and monitoring of allergy: The MeDALL allergenchip, Methods 2014, 66, 106−119.

48

Chapter 3 A

Novel

LC-MS

Approach

for

Characterizing

Immobilized Antibody Orientation

49

Abstract
The molecular orientation of antibodies immobilized on solid surface plays a significant role in
the performance of immunoassays. Using surface analysis techniques and multivariate analysis
tools to characterize the orientation of surface immobilized antibodies in naïve environment are
still required. Here we report a novel method utilizing limited proteolysis on surface immobilized
antibodies to probe their orientation. The limited protease access to the antibody layer resulted in
different compositions of proteolytic peptides generated from either Fab or Fc regions. With the
help of liquid chromatography-mass spectrometry (LC-MS) for peptide analysis, the limited
proteolysis kinetics were studied and the information of antibody orientation information could
thus be interpreted. This novel approach is able to distinguish protein A/G oriented antibodies from
randomly immobilized antibodies via EDC-NHS chemistry.
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3.1 Introduction
Antibodies (Abs) are the key elements to all kinds of immunoassay, where they should be
immobilized onto solid surface within the sensor. Currently, immunoglobulin G (IgG, ~150 kDa)
is the most commonly used antibodies in the immunoassays, although relative smaller molecules
derived from the whole antibody such as single-domain antibody were also reported.1 One IgG
antibody contains two identical light and heavy chains, respectively, while certain numbers of
disulfide bonds are formed between light - heavy chains or heavy - heavy chains, resulting in a
characteristic Y-shape. The chains can also be cataloged into variable (V) and constant (C) regions
according to their amino acid sequence conservation.2 Therefore, the combination of light/heavy
chain and variable/constant region results in different domains in the IgG antibodies, namely VL,
VH, CL, CH1, CH2 and CH3 domains (Figure 1.1B). In addition, the enzyme papain can cleave an
IgG antibody into two Fab (fragment antigen-binding) fragments and one Fc (fragment
crystallizable) fragment (Figure 1.1C), so the terms, Fab and Fc regions, are also used here to
describe the structure of Abs.3 Apparently, in order to achieve a good recognition of antigens,
antigen-binding region (Fab regions) must be oriented towards to the solution containing antigens
while the non-binding region (Fc region) should be directly anchored onto the surface.4
The routinely used strategies for antibody immobilization are through direct absorption or linkage
of amine/carboxyl group of antibodies, which would result in randomly oriented antibodies. Thus,
many novel immobilization strategies were reported to control the IgG antibody orientation,
aiming for an improved performance of immunoassay.5,6 These reported strategies include specific
electrostatic adsorption, site-specific coupling, recombinant antibodies, use of IgG-binding ligand
(e.g. protein A and protein G), and so on.6 Among them, use of IgG-binding proteins is a good
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choice as no chemical modifications is performed onto the antibody molecules, As a result, the
antibody bioactivities would be remained to a great extent. The commercial protein A and protein
G are two biologically engineered bacterial cell wall proteins that only carry several Fc binding
sites with good specific binding affinities for certain antibody Fc regions.7 Their chimeric protein,
protein A/G, results in the effective binding to the Fc region of antibodies from nearly any
mammalian species. 8 The binding between antibodies and protein A/G shows reasonable
reliability and higher affinity under philological conditions than protein A or G alone,9 which
makes it a good option to achieve oriented antibodies.
Evidence of protein A (/G) based immunoassays rarely gives the characterization information
regarding antibody orientation, although improved antigen binding capacities/efficiencies were
observed.1, 10 Such insufficiency is partially due to the short of techniques that are able to
characterize the orientation of surface immobilized proteins, while distinguishing the differences
among orientation, denaturation and conformational changes. 11 One kind of methods is to measure
the thickness of antibody layer since antibody has different length in all three dimensions (14.3
nm × 7.7 nm × 4.0 nm). Using atomic force microscopy (AFM), dual polarization interferometry
(DPI), neutron reflectometry (NR), or spectroscopic ellipsometry (SE), the thickness of the layer
and the shape of the proteins can be compared with the ideally orientated antibodies and give
orientation information. 12 - Another kind of approach is to acquire the amino acid component
information regarding the surface of antibody layers. Time-of-flight secondary ion mass
spectrometry (TOF-SIMS) coupled with principal component analysis (PCA) is most commonly
applied in this category. 16,17 This technique starts with the ion bombardment to the antibody layer
(sampling depth 1~3 nm) by a pulsed primary ion beam. The resulting charged ions (secondary
ions) are analyzed by the time-of-flight mass spectrometry, yielding an amino acid composition
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percentage of antibody layer. Since the Fab and Fc regions contain different amino acid
composition percentage, PCA is used to distinguish the data sets from differently oriented antibody
surfaces and identify if the layer surface has more Fab or Fc region.
In this work, carboxylated magnetic particles (MP) were used as a platform for antibody
immobilization as MP mainly provides a compelling approach for convenient separation.
Antibodies were immobilized either through protein A/G mediated Fc binding or via
amine/carboxyl group linkage, which would result in oriented or randomly immobilized antibodies
on the surface. (Scheme 3.1) Instead of using primary ion beam to generate ions for analysis,
limited trypsin proteolysis was employed under the nondenatured condition, meaning the
proteolysis only happened on the surface of antibody layer (Scheme 3.2). This limited trypsin
proteolysis yielded several representative peptides identified in either Fab or Fc regions, which
can help us to characterize the components of the antibody layer surface and interpret antibody
orientation information. Unlike two methods previously discussed, the orientation information
acquisition is performed in a nondenatured “wet” environment, which greatly reveals a more native
conformation of antibodies. The resulting peptides would be much easier to identify and quantified
due to the well-established liquid chromatography-mass spectrometry (LC-MS) techniques.
Obviously, this limited proteolysis analysis technique permits a more accurate presentation of the
surface immobilized antibody orientation states.
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Scheme 3.1 Schematic for antibody immobilization using two different strategies which result in
oriented or randomly immobilized antibodies on the magnetic particle (MP) surface. EDC (1-ethyl3-(3-dimethylaminopropyl)

carbodiimide)

and

NHSS

(N-hydroxysulfosuccinimide)

are

commonly used coupling agents to link proteins onto carboxylated MPs.

Scheme 3.2 Schematic for characterizing antibody orientation using limited trypsin proteolysis
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3.2 Experimental
3.2.1 Chemicals and materials
A monoclonal mouse IgG2a antibody specific for human prostate specific antigen (PSA) was
obtained from R&D Systems, Inc. (Catalog # MAB13442). Carboxylated magnetic particles (MP)
were from Polysciences, Inc.. Genetically engineered protein A/G (ProA/G) was from Biovision
Inc. Sequencing grade modified trypsin was obtained from Promega Corporation. Water,
acetonitrile (ACN), formic acid (FA), and ammonium acetate (NH4Ac) are all of LC-MS reagents
from Sigma-Aldrich. A peptide sequencing standard, YAEGDVHATSKPARR, was also
purchased from Sigma-Aldrich.

3.2.2 Preparation of MP-Ab, MP-ProA/G-Ab and MP-trypsin conjugates
MP-Ab, MP-ProA/G-Ab and MP-trypsin conjugates were prepared according to the
manufacturer’s protocol and our previous study 18 with minor modification. First, 25 μL of
carboxylated MPs (1 µm diameter, 20 mg mL−1) were magnetically washed twice using 250 μL of
50 mM 2-(N-morpholino)ethanesulphonic acid (MES) buffer (pH 5.2). Then the carboxylated MPs
were activated using aqueous solution containing 400 mM 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and 100 mM N-hydroxysulfosuccinimide (NHSS) for 15 min, followed by
coupling amine groups of Ab, ProA/G, or trypsin in 10 mM acetate buffer (pH 5.0). The unreacted
EDC/NHSS derivatives on the MP conjugates were further quenched by 100 mM ethanolamine
(pH 8.0). The MP-ProA/G conjugates were then mixed with Ab in 50 mM NH4Ac buffer (pH 8.0)
to prepare MP-ProA/G-Ab conjugates. All MP conjugates were magnetically washed three times
by 50 mM NH4Ac buffer (pH 8.0) before trypsin digestion step.
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3.2.3 Trypsin digestion under nondenatured conditions
Ab, MP-Ab conjugates, and MP-ProA/G-Ab conjugates were reconstituted in 400 μL of 50 mM
NH4Ac buffer (pH 8.0) containing trypsin or MP-trypsin in a trypsin/Ab (w/w) ratio of 1:1,
respectively and the resulting mixtures were incubated at 37°C with shaking for 12 h. The digestion
was stopped by adding 10% FA to approximately pH 3. A solution of internal standard peptide,
YAEGDVHATSKPARR, was then spiked for normalization purpose. Then the MPs were
magnetically removed and discarded while the supernatants containing tryptic peptides were
filtered through an AcroPrep™ 96-well filter plate (MWCO = 3 kDa, Pall Corporation) and
subjected to LC-MS/MS analysis.
All samples were pipetted in autosampler vials containing glass inserts (150 µL low volume insert
with plastic spring, Waters Corporation).

3.2.4 PSA capture using MP conjugates and pellet digestion
1 mL of 10 ng mL-1 prostate specific antigens (PSA) were incubated with 20 μL of resulting MPAb and MP-ProA/G-Ab conjugates at room temperature, respectively. After certain time intervals,
MPs were magnetically separated and thoroughly wash by 10 mM phosphate-buffered saline
containing (PBS, pH 7.4). Then pellet digestion was used to obtain tryptic peptide for PSA
quantification.19,20 First, urea was added to give the solutions of 6 M urea, then protein reduction
was carried out by adding 2 µL of 200 mM dithiothreitol (DTT) to the sample solution, followed
by a 30 min incubation at room temperature. Then the samples bearing reduced free thiol groups
were alkylated by utilizing 2 µL of 1 M IAA (iodoacetamide) in the darkness for another 30 min
at room temperature. Excess IAA was further neutralized by 10 µL of 200 mM DTT solution. The
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resulting samples were chilled by adding cold (-20°C) acetone; another 5 volumes of cold acetone
were then added sequentially, followed by overnight incubation at -20°C. After centrifugation at
13,000 rpm under 4°C for 30 min, the supernatants were discarded and the resulting pellets were
washed with 86% acetone three times. The pellets were then air-dried and digested with trypsin in
a trypsin/protein (w/w) ratio of 1:100 for 18 hours. The trypsin digestion was stopped by adding
10% FA to approximately pH 3. A solution of internal standard peptide, YAEGDVHATSKPARR,
was then spiked for normalization purpose. Then the tryptic peptides were filtered through an
AcroPrep™ 96-well filter plate (MWCO = 3 kDa, Pall Corporation) and subjected to LC-MS/MS
analysis.
The same procedures were applied to free antibody and PSA molecules in order to establish their
calibration plots.

3.2.4 LC-MS instrumentation and analysis
For the analysis of digest samples, a Thermo Scientific Dionex Ultimate 3000 UPLC system was
interfaced to either an AB Sciex QSTAR Elite quadrupole time-of-flight (Q-TOF, for identification
purpose) or a Thermo Scientific TSQ Quantiva triple quadrupole (QqQ, for quantification purpose)
mass spectrometer. Peptide separation was conducted using a Jupiter C18 column (150 × 0.50 mm,
5 µm, Phenomenex), with a flow rate of 15 µL min-1 and a column temperature of 35°C. The
gradient used was listed in Table 3.1, where solvent A is 98.8% water, 1.0% ACN and 0.2% FA,
and solvent B is 1.0% water, 98.8% ACN and 0.2% FA.

57

Table 3.1 UPLC gradient used for tryptic peptide identification and quantification.
tryptic peptide identification

tryptic peptide quantification

time/min

%B

time/min

%B

0
3
53
53.5
56.5
56.6
60

1
1
40
90
90
1
1

0
3
18
18.5
21
21.1
25

1
1
19
90
90
1
1

Both mass spectrometers were operated in positive mode. Information-dependent acquisition (IDA)
was performed on the QSTAR mass spectrometer, which ran a full ion scan survey in the m/z ratio
range of 300 ~ 1500 and charge state from +2 to +4, followed by MS/MS acquisition on the most
prominent precursor ions from the survey scan. The selected ion would be excluded from MS/MS
acquisition in the following 15 seconds. Key parameters of QSTAR MS instrument were set as
curtain gas (CUR) = 30 arbitrary units, ionspray voltage (IS) = 5000 V, temperature (TEM) =
300°C, ion source gas 1 (GS1) = 15 arbitrary units, ion source gas 2 (GS2) = 20 arbitrary units,
declustering potential (DP) = 80 V, focusing potential (FP) = 280 V, declustering potential 2 (DP2)
= 15 V, ion release delay (IRD) = 6 arbitrary units, ion release width (IRW) = 5 arbitrary units,
collision gas (CAD) = 5 arbitrary units.
Multiple reaction monitoring (MRM) was operated on the TSQ Quantiva mass spectrometer,
which ran multiple m/z transitions (precursor/product ion pairs) in a cycle time of 1 second (Table
3.2). Key parameters of MRM-MS instrument were set as ion source type = H-ESI, spray voltage
(static) positive ion = 3900 V, sheath gas = 20 arbitrary units, aux gas = 7 arbitrary units, sweep
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gas = 2 arbitrary units, ion transfer tube temperature = 300°C, vaporizer temperature = 33°C, APPI
lamp = Not in use. MRM properties were set as use cycle time = checked, cycle time = 1 s, use
calibrated RF lens = checked, Q1 resolution (FWHM) = 0.7, Q3 resolution (FWHM) = 0.7, CID
gas = 1.5 mTorr, source fragmentation = 0 V, chrom filter = 3 s, display retention time = unchecked.

Table 3.2 MRM transitions and parameters used in the tryptic peptide quantification. Unless
otherwise noted, the tryptic peptides were identified from the monoclonal mouse IgG2a antibody
specific for human (PSA).
selected peptide

transition mass filter, m/z

Role

DIVLTQSPATLSVTPGDR 34.1

935.499  1113.590 (y11)
935.499  1200.622 (y12)
935.499  9445.500 (y9)

Quantification
Confirmation
Confirmation

YASQSISGIPSR

23.8

633.327  616.3413 (y6)
633.327  816.4574 (y8)
633.327  729.4254 (y7)

Quantification
Confirmation
Confirmation

WKIDGSER

19.2

495.753  676.326 (y6)
495.753  563.242 (y5)
495.753  448.215 (y4)

Quantification
Confirmation
Confirmation

QNGVLNSWTDQDSK

29.4

796.370  1080.459 (y9)
796.370  966.4163 (y8)
796.370  879.3843 (y7)

Quantification
Confirmation
Confirmation

TSTSPIVK

16.5

416.742  644.3978 (y6)
416.742  543.3501 (y5)
416.742  456.318 (y4)

Quantification
Confirmation
Confirmation

19.2

496.274  678.3417 (y6)
496.274  791.4258 (y7)
496.274  591.3097 (y5)

Quantification
Confirmation
Confirmation

LSISKDNSK

CE, V
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Table 3.2 continued
selected peptide

CE, V

transition mass filter, m/z

Role

VVSALPIQHQDWMSGK

19.2

599.310 (+3)  799.3932 (y142+)
599.310 (+3)  720.3586 (y122+)
599.310 (+3)  663.8166 (y112+)

Quantification
Confirmation
Confirmation

DLPAPIER

17.8

455.753  514.2984 (y4)
455.753  682.3883 (y6)
455.753  585.3355 (y5)

Quantification
Confirmation
Confirmation

33.4

914.463  1057.487 (y9)
914.463  1170.571 (y10)

Quantification
Confirmation

914.463  960.4343 (y8)

Confirmation
Quantification
Confirmation
Confirmation

APQVYVLPPPEEEMTK

APQVYVLPPPEEEMTKK

20.8

652.676 (+3)  593.2946 (y102+)
652.676 (+3)  649.8367 (y112+)
652.676 (+3)  544.7683 (y92+)

TELNYK

15.4

384.200  537.3031 (y4)
384.200  666.3457 (y5)
384.200  424.2191 (y3)

Quantification
Confirmation
Confirmation

YASQSISGIPSR (internal 17.8
standard, IS)

553.285 (+3)  712.3737 (y132+)
553.285 (+3)  747.8922 (y142+)
553.285 (+3)  561.8282 (y102+)

Quantification
Confirmation
Confirmation

SVILLGR (from prostate 15.2
specific antigen, PSA)

379.250 (+2)  571.3926 (y5)
379.250 (+2)  458.3085 (y4)
379.250 (+2)  345.2245 (y3)

Quantification
Confirmation
Confirmation

3.2.5 Data analysis
The LC-MS/MS data in .wiff format from IDA (QSTAR) were submitted to a local mascot server
for an MS/MS protein identification search using Mascot Daemon (version 2.3.0) against NCBInr
database (NCBI non-redundant, NCBI: National Center for Biotechnology Information). Key
identification parameters were set as Taxonomy = Mus musculus (house mouse), Fixed
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modifications = none, Variable modifications = non, Enzyme = trypsin, Number of allowed missed
cleavages = 1; Peptide mass tolerance = 100 ppm; MS/MS mass tolerance = 0.8 Da, Charge state
= +2, +3 and +4.
The alignments of MASCOT predicted peptide sequences with the peptide sequence from a known
mouse IgG2a antibody (PDB entry 1IGT) were conducted using two web-based bioinformatics
tools: SIM - Alignment Tool for protein sequences 21 and T-COFFEE Multiple Sequence
Alignment Server22. Then the results were manually summarized as Figure 3.2.
A freely-available, open-source bioinformatics tool, Skyline23, was used to generate the transition
list for MRM-MS (Table 3.2). The obtained MRM data were then imported back to Skyline
application for determination of peak areas from each of the monitored transitions. The 1st ranking
peak area of each peptide transition is used for protein quantification (Table 3.2).

3.3 Results
3.3.1 Tryptic peptide identification
The target mouse monoclonal IgG2a antibodies were digested by trypsin under a nondenatured
condition. The resulting peptide mixture was then sent for LC-MS/MS (Q-TOF) analysis with an
unknown screening method called information dependent acquisition (IDA). The resulting peptide
MS/MS spectra (Figure 3.1) were then searched for peptide sequence match against NCBInr
peptide database using the MASCOT MS/MS ion search engine. Several tryptic peptides were
successfully identified (Table 3.3) to either light chain or heavy chain of mouse antibodies, which
is in a good accordance with the fact that the antibody is a mouse IgG2a antibody. Those identified
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peptides were then aligned with a model mouse IgG2a antibody (PDB entry 1IGT) of known
sequence and 3D structure to assign their belonging domains (Figure 3.2 and Table 3.3).

Figure 3.1 MS/MS collision-induced dissociation (CID) spectra of the tryptic peptide ions derived
from a mouse monoclonal IgG2a antibody. The peptide sequences are identified by MASCOT
MS/MS ion search engine, and shown here.
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Figure 3.2 Alignment of Mascot software predicted peptides (red) with the sequences derived
from a mouse IgG2a antibody (PDB entry 1IGT): asterisks (*) indicate identical sites in the
sequence alignments; colons (:) represent sites with conserved substitutions.
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Table 3.3 Mascot software predicted peptide sequences from target IgG2a antibody are listed with
amino acid sequences, domain from each chain, and region
No.

Peptide sequence

Domain

Region

1

DIVLTQSPATLSVTPGDR

VL

Fab

2

YASQSISGIPSR

VL

Fab

3

WKIDGSER

CL

Fab

4

QNGVLNSWTDQDSK

CL

Fab

5

TSTSPIVK

CL

Fab

6

LSISKDNSK

VH

Fab

7

VVSALPIQHQDWMSGK

CH2

Fc

8

DLPAPIER

CH2

Fc

9

APQVYVLPPPEEEMTK

CH3

Fc

10

APQVYVLPPPEEEMTKK

CH3

Fc

11

TELNYK

CH3

Fc

3.3.2 LC-MS/MS based peptide quantitative analysis
The resulting tryptic peptides were then sent for the LC-MS/MS analysis and a multiple reaction
monitoring (MRM) method was optimized to guarantee the best performance for the relative
quantification of these peptides. Here, we chose one mass transition which gave the largest peak
area for the protein quantification purpose and other two transitions for confirmation purpose
(Table 3.2 and Figure 3.3).
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Figure 3.3 The representative MRM chromatograms containing three transitions for a single
tryptic peptide for quantification purpose. The peptides are: 1, DIVLTQSPATLSVTPGDR; 2,
YASQSISGIPSR; 3, WKIDGSER; 4, QNGVLNSWTDQDSK; 5, TSTSPIVK; 6, LSISKDNSK;
7,

VVSALPIQHQDWMSGK;

8,

DLPAPIER;

9,

APQVYVLPPPEEEMTK;

10,

APQVYVLPPPEEEMTKK; 11, TELNYK; 12, YAEGDVHATSKPARR, as an internal standard.
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Figure 3.4 A representative extracted ion chromatogram (XIC) of 12 MRM transitions (peaks),
including 11 tryptic peptides from target antibody and one internal standard. The peptides are: 1,
DIVLTQSPATLSVTPGDR; 2, YASQSISGIPSR; 3, WKIDGSER; 4, QNGVLNSWTDQDSK; 5,
TSTSPIVK;

6,

LSISKDNSK;

APQVYVLPPPEEEMTK;

10,

7,

VVSALPIQHQDWMSGK;

APQVYVLPPPEEEMTKK;

8,
11,

DLPAPIER;
TELNYK;

9,
12,

YAEGDVHATSKPARR, as an internal standard.

Certain peptides were selected based on following criteria to ensure the sensitivity, specificity and
robustness of the peptide quantification. Selection criteria include: (1) avoid peptides containing
methionine (M) and cysteine (C) as they are prone to chemical modification; (2) avoid peptides
containing arginine-arginine (R-R), lysine-lysine (K-K) or any missed cleavage sites to minimize
inconsistent tryptic cleavage; (3) avoid too short and too long peptides as being too short may lack
the selectivity and too long may affect the sensitivity; (4) select peptides giving relative high signal
intensity to ensure the sensitivity of the assay. As the result, four representative peptides from four
different regions of the antibody were selected to monitor the trypsin digestion kinetics of MP-Ab
and MP-ProA/G-Ab, including YASQSISGIPSR from VL domain, Fab region; TSTSPIVK from
CL domain, Fab region; DLPAPIER from CH2 domain, Fc region; and TELNYK from CH3 domain,
Fc region.
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3.3.3 The amount of antibodies on MP conjugates
The amount of antibodies on MP-Ab and MP-ProA/G conjugates were estimated using pellet
trypsin digestion followed by LC-MS/MS analysis. In brief, different amount of free antibodies
were denatured by urea, reduced by dithiothreitol (DTT) and alkylated by iodoacetamide (IAA),
followed by acetone precipitation and trypsin digestion. The resulting peptide mixture was further
spiked with internal standard and analysed by LC-MS/MS as described above. Several excellent
calibration curves were established showing the ratio of peak area of antibody peptide to the
internal standard peptide is proportional to the amount of antibodies (Figure 3.5). The different
slopes are due to different electrospray ionization efficiency and variable fragmentation patterns
of each peptides. The peptide YASQSISGIPSR from VL domain is selected for antibody
quantification purpose as (1) it is from variable region so it is a unique peptide for this monoclonal
antibody, (2) it has no lysine residue (K) so it would not covalently link to the carboxylated MP
via EDC/NHSS based amine-carboxyl conjugation and (3) it has largest slope in the calibration
curves among other peptides, thus the analytical sensitivity is high.
Certain amount of MP-Ab and MP-ProA/G conjugates went through the same procedure and the
amount of antibodies was estimated and eventually converted to the number of antibodies per
particle (other assumptions include molecular weight of this mouse IgG antibodies is ~150 kDa
and 1 mL of 20 mg mL-1 MP is corresponding to 2.0 × 109 particles according to the manufacturer):
139,000±7,000 antibody molecules were estimated on one MP-Ab conjugate while 145,000±9,000
antibody molecules were estimated on one MP-ProA/G-Ab conjugate, which is in a good
accordance with our previous report.24 No significant difference of antibody numbers per particle
were found between MP-Ab and MP-ProA/G-Ab conjugates (t-test, p > 0.05). Thus, the average
antibody numbers, ~142,000 antibody molecules were estimated on the 1.5 μm MP, indicating
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each antibody would occupy an average of 7 nm × 7 nm area, which is comparable to its dimension
of 14.3 nm × 7.7 nm × 4.0 n m.1 However, considering the irregular shape of MP which provide
20 to 30 times that of the same size spherical particle according to the manufacturer, an average of
35 nm × 35 nm area is estimated, which is over the dimension of one antibody molecule.

Figure 3.5 Calibration plotting between peak area ratio of peptide YASQSISGIPSR from the
antibody to internal standard peptide and the mass of antibodies. The different slopes are due to
different electrospray ionization efficiency and variable fragmentation patterns of each peptides in
mass spectrometer.

3.3.3 Trypsin and MP-trypsin digestion kinetics
Free trypsin enzymes were first applied to digest MP-ProA/G-Ab and MP-Ab conjugates under
nondenatured conditions. The resulting peptide mixture was then sent for LC-MS/MS
quantification. After 10 h, a plateau of MS signals was observed (Figure 3.6), indicating the
digestion is completed. In the MP-ProA/G-Ab conjugates, a significant enhanced digestion rate at
initial stage was observed for the peptide YASQSISGIPSR from VL domain, Fab region, indicating
the variable regions of the immobilized IgG2a antibody are oriented toward the trypsin solution
due to the Fc binding by protein A/G. However, in the case of MP-Ab, no significant difference
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among the digestion rates of these four peptides, indicating that the antibodies were randomly
immobilized and trypsin enzymes have the almost equal opportunity to get access to these regions
and perform digestion.

Figure 3.6 Trypsin digestion kinetics study for (A) MP-ProA/G-Ab and (B) MP-Ab conjugates.
The peptide sequences and positions are shown on the right side.

As trypsin is a relative small enzyme (~ 23 kDa) compared to antibody (~150 kDa) while
antibodies will not fully cover the MP surface, it is possible that trypsin enzymes diffuse through
the gaps between antibodies, and get access to the bottom part of antibody layer. As a result, trypsin
may perform digestion from the inside of the antibody layer to the outside, which is not desired in
orientation characterization. Therefore, trypsin enzymes were further immobilized onto MPs as
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MP-trypsin, and thus, due to the steric effects, the MP-trypsin would more focus on the surface of
antibody layer. As a result, in the case of MP-ProA/G-Ab conjugates, a distinguishable digestion
rates from variable region, then constant Fab region, finally to constant Fc region can be observed
at the initial 6 h period (Figure 3.6). Such trend can also be observed in the case of MP-Ab
conjugates, but not that obvious, indicating that EDC-NHS chemistry resulted in large amount of
randomly immobilized antibodies.

Figure 3.7 MP-trypsin digestion kinetics study for (A) MP-ProA/G-Ab and (B) MP-Ab conjugates.
The peptide sequences and positions are shown on the right side.
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3.3.4 PSA capture using MP conjugates and PSA quantification
Similar to antibody quantification in section 3.3.2, the amount of PSA captured onto MP-Ab and
MP-ProA/G conjugates were estimated using pellet trypsin digestion followed by LC-MS/MS
analysis. A peptide SVILLGR from PSA molecule is selected for PSA quantification according to
previous report.25 An excellent calibration curve was then established showing the ratio of peak
area of peptide SVILLGR to the internal standard peptide is proportional to the amount of PSA
(Figure 3.8A). Using this calibration curve, the amount of PSA molecules captured onto MP-Ab
and MP-ProA/G-Ab conjugates were estimated. And as expected, MP-ProA/G conjugates not only
capture more PSA but in a faster manner than MP-Ab conjugates (Figure 3.8B).

Figure 3.8 (A) Calibration plotting between peak area ratio of peptide SVILLGR from PSA to
internal standard peptide and the mass of PSA. The inset shows the dynamic range of this
calibration curve starts at 2 ng PSA. (B) Binding of 10 ng mL-1 PSA to the MP-Ab (red) and MPProA/G-Ab (blue) conjugates though incubation time.
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3.4 Discussion
Analyses of antibody layer thickness and surface amino acid composition are two current
approaches for immobilized antibody orientation characterization, which are at the levels of
protein and amino acid, respectively. Here, we offered an alternative characterization approach at
the peptide level, which fills in the current gap. Peptides have much more biological specificity
than amino acids and they naturally carry position information. The different trypsin digestion
rates of peptides from different antibody regions directly reflect the circumstances of antibody
orientation. The sequence specificity of peptides also make this approach adaptable to characterize
orientation of other proteins besides antibodies. Thus using peptides as antibody orientation
interrupters is an advantageous approach. Furthermore, unlike other two current approaches which
normally place the antibodies in a dry environment and take the risks of antibody denature, the
antibodies in our approach were always under a nondenatured condition, therefore their native
conformations were maintained to the best.
Immobilized trypsin magnetic particle (MP-trypsin) provided a more accurate peptide composition
of antibody layer than free trypsin, since MP-trypsin would more focus on the surface instead of
other reaction fields. As a result, such effective solid-solid digestion has made it possible to
minimize the sample complexity of peptide mixture. Meanwhile, it would be easier to stop the
digestion by applying magnetic field; no contamination of the extra trypsin into the analyte or no
further peptide purification steps such as solid phase extraction are needed. MP-trypsin digestion
is able to distinguish peptides from constant part of Fab and Fc regions (Figure 3.7A), therefore
knowing the sequences in the variable region is not required using MP-trypsin digestion strategy.
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3.5 Conclusions
In this work, protein A/G was used to increase the chance of Fc “stem-down” oriented patterns by
binding to the Fc region of antibody. Limited proteolysis using free trypsin and immobilized
trypsin magnetic beads were employed and the orientation of antibodies was analyzed. Results
showed protein A/G can significantly enhance the percentage of Fab “heads-up” while Fc “temdown”. And this limited trypsin proteolysis can be extended in principle to virtually analyze
orientation of any proteins besides antibodies.
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Chapter 4 LC-MS studies of protein and antibody isolation from
human serum using selective nanoparticles
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Abstract
Due to unsurpassed specificity and excellent sensitivity, MS-based assays have been increasingly
applied for the quantitative analysis of proteins, especially antibodies. Here, a set of LC-MS
approaches, named the surrogate peptide approach and the intact protein approach, were employed
to analyze the proteins and antibodies isolated from human serum in the development of our
specially synthesized magnetic nanoparticles with selective protein/antibody binding nanopockets.
In detail, both above approaches of protein analysis were conducted for relative quantification of
human serum albumin (HSA) in the application of albumin depletion using albumin binding
nanoparticles. Our nanoparticles showed comparable depletion efficiency but much lower cost
compared to the commercial column. In addition, surrogate peptide approach was further used to
quantify the proteins isolated by antibody binding nanoparticles (e.g., target antibodies and
impurity proteins). Our antibody binding nanoparticles can isolate two folds more IgG antibodies
than the commercial protein A magnetic beads under the same price, showing a great promise for
antibody purification in the therapeutic antibody industry.
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4.1 Introduction
Due to unsurpassed specificity and excellent sensitivity, MS-based assays have been increasingly
applied for the quantitative analysis of proteins, especially antibodies. There are two major
strategies of protein analysis, as known as top-down and bottom-up strategies, or in practice, the
intact protein approach and the surrogate peptide approach, respectively (Scheme 4.1).

Scheme 4.1 MS-based bioanalysis of proteins using (A) the surrogate peptide approach and (B)
the intact protein approach

Part of work in this chapter used intact protein approach since it is a “true” measurement of the
target protein and minimal pretreatment was required. Although this approach is limited to small
protein analysis (molecular weight < 20 kDa), we still used this approach for human serum albumin
(HSA) analysis since HSA is the most abundant (> 50%) proteins in the human serum. A single
TOF mass analyzer was used as (1) TOF could give a better resolution to identify proteins and
their derivatives after biotransformation and post-translational modifications, (2) fragmentation of
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a whole protein may not create one or more major product ions for MRM detection. Overall, using
such intact protein approach is feasible with relative semi-quantification but surrogate peptide
approach is still recommended as it can provide a satisfactory assay sensitivity and selectivity.
The surrogate peptide approach is well established and become the most commonly used strategy
for MS-based protein quantification due to its high sensitivity and specificity and broad
compatibility with QqQ MS analysis. In this chapter, most protein (and antibody) quantifications
were achieved using such approach. In this approach, the target protein is digested to peptides and
one (or more) unique peptide(s) from the digests are identified and used for protein quantification.
Thus and so the surrogate peptide should be selected wisely to ensure the sensitivity, specificity,
and robustness of the assay. Selection criteria include: (1) avoid peptides containing methionine
(M) and cysteine (C) as they are prone to chemical modification; (2) avoid peptides containing
arginine-arginine (R-R) and lysine-lysine (K-K) to minimize inconsistent tryptic cleavage (if the
tryptic digestion is used); (3) avoid too short and too long peptides as being too short may lack the
selectivity and too long may affect the sensitivity (appropriate length is ~ 8 - 20 amino acids).
Currently, many bioinformatics tools have been developed to digest protein in silico by a selected
proteolytic enzyme (e.g., trypsin, Lys-C, Arg-C, Lys-N) and give predicted peptides for protein
analysis. In this dissertation, a powerful bioinformatics tool called Skyline1, was used throughout
the whole procedures of surrogate peptide approach. First, protein sequences were obtained from
UniProt database2 as a format of FASTA and imported into Skyline, which automatically generates
the predicted peptides. Surrogate peptides were then selected based on previous reports, and a
transition list was exported using the same Skyline. Afterwards, MRM MS analyses were
performed on a series of samples, and the results were sent back (imported) to Skyline again to
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calculate the peak area of each peptide in the chromatograms. With the help of Skyline, MRM MS
methods were easy to make and the data processing were extremely facilitated.
Experimental digestion of target proteins to generate peptides efficiently is also critical in this
surrogate peptide approach. A conventional workflow includes internal standard spiking, clean-up
at protein level, protein denaturation, reduction, alkylation, then digestion and clean-up at the
peptide level, which is time-consuming and labor-intensive, especially at two clean-up steps. In
this dissertation, we used a straightforward and fast trypsin digestion method called pellet digestion,
which used acetone precipitation to form protein pellet and trypsin digestion was conducted
afterward. The resulting peptide mixture could be used directly for LC-MRM MS analysis without
further clean-ups. Such pellet digestion method is good enough to provide a consistent digestion
and generate the satisfactory surrogate peptide for MS analysis.
As the most abundant proteins in serum/plasma, HSA must be depleted from the serum/plasma
sample prior to proteomic analyses, particularly when aiming at target proteins within pg mL-1 or
even lower concentration ranges.3,4 There are a lot of commercially available kits for albumin
removal, most of which are based on HSA specific antibodies or some proprietary HSA binding
proteins. However, the cost, stability, and reusability of these products are the big issue as proteins
are used as the HSA capture agents. Our group developed a novel, robust, reusable, inexpensive
magnetic nanoparticle featuring stable surface HSA binding nanopockets which can selectively
and efficiently remove HSA from serum.5 Such magnetic nanoparticles, as we name NPHSA in this
chapter, were made by templating HSA proteins on 200 nm silica-coated paramagnetic
nanoparticles via polymerization of 4 organo-silane monomers on the particle surface. The used
monomers have different side chains providing hydrophobic, hydrophilic and H-bonding
interactions with HSA which closely mimic features of binding sites of antibodies.
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Many characterization experiments for the NPHSA were conducted, and its binding capacity is
estimated as 21 mg HSA per gram NPHSA. To further examine its HSA removal capacity, NPHSA
was used for HSA depletion of a human serum sample (Scheme 4.1) and compared with a
commercial single-use ProteoExtract® albumin removal system (PEHSA) from Millipore. Two LCMS(/MS) approaches were developed for separation, characterization, and quantification of HSA
in human serum before and after using NPHSA and PEHSA depletion. Some HSA molecules in serum
have been confirmed with oxidative modification and/or glycation using top-down MS analyses
of intact HSA molecules. The top-down analyses also gave a semi-quantification of HSA in
undepleted and depleted human serum, showing approximately 90% HSA was removed after
treatment of NPHSA or PEHSA. Besides top-down analyses, conventional bottom-up MS analyses
of peptides from HSA digest were performed and again confirmed approximately 90% HSA was
removed after depletion.

Scheme 4.2 Schematic for depleting human serum albumin (HSA) from human serum using homemade HSA specific magnetic nanoparticle (NPHSA). The undepleted and depleted human serum (in
the 1st and 4th tube, respectively) will be collected for LC-MS analysis.
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Antibodies (i.e., immunoglobulins, Ig), especially therapeutic monoclonal antibodies (mAb) has
occupied an enormous fraction of the global biopharmaceutical market, and its market share keeps
growing. 6 There are approximately 30 FDA approved/under review antibody-based drugs for
therapeutic use in various diseases.7 In addition, tremendous antibodies are commercialized for
research uses, such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence
(IF). Apparently, above biopharmaceutical or commercial products must have very high purify,
therefore, the isolation/purification methods of antibodies are always critical steps for bulk
antibody production.8 For example, to purify mAbs from Chinese hamster ovary (CHO) cells, a
combination of three-column chromatography process is typically employed, which includes
protein A affinity chromatography as an initial capture step, followed by cation exchange and
anion exchange chromatography as polishing steps and a virus filtration (VF) step, respectively.9
Currently, protein A-based affinity columns, resins, and magnetic beads are extensively used for
antibody purification, since the protein A ligand has a high affinity for the crystallizable fragment
(Fc) of antibodies, which enables the efficient capture of mAbs from the biological matrix (e.g.,
all kinds of serum and cell culture fluid).
Even though above protein A-based antibody purification steps are well established, the use of
protein A affinity step is expensive, which accounts for around 35% of the total raw material costs
for downstream purification. 10 The high cost is partially due to the material itself, as well as
partially due to the instability of proteins. Thus, with growing demand for commercial antibodies
and increasing market competition, there is a critical need in the development of cost-effective and
stable affinity purification systems that do not involve protein A. Following our design of a robust,
reusable, inexpensive magnetic nanoparticle featuring stable surface HSA binding nanopockets,5
we developed magnetic nanoparticles bearing protein A-like nanopockets which can reversibly
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bind to antibodies, as we name NPA in this Chapter (Scheme 4.2). Such NPA particles were made
by templating mouse IgG2a antibody proteins on 200 nm silica-coated paramagnetic nanoparticles
via polymerization of four organo-silane monomers on the particle surface. In detail, periodate
oxidation on polysaccharide moieties on Fc regions of antibodies yielded aldehyde groups for
reversible but covalent linkage to nanoparticle surface bearing amine groups. Thus IgG2a
antibodies contacted with nanoparticles with their Fc regions. Then four monomers have different
side chains provided hydrophobic, hydrophilic and H-bonding interactions with antibody Fc
regions, which fully mimic the binding behaviors of protein A molecules. Many characterization
experiments for the NPA were conducted such as affinity, specificity, stability and reusability. The
synthesized artificial pockets were found to bind to antibodies similarly like protein A using
surface plasmon resonance (SPR) methods and binding isotherm assays.

Scheme 4.3 Schematic for recover antibodies from serum using home-made protein A-like
magnetic nanoparticle (NPA). The serum before and after antibody purification (in the 1st and 6th
tube, respectively) will be collected for LC-MS/MS analysis.
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According to previous HSA study, LC-MS/MS using surrogate peptide approach holds a great
potential for identification and quantification of antibodies and other proteins.11,12 Here, using such
method, we analyzed not only the abundant serum antibodies such as IgG, IgA and IgM antibodies,
but also other serum proteins which might adsorb onto the magnetic particles due to non-specific
binding. In addition, this LC-MS/MS method can multiplex all subclasses along with total IgG
antibodies using subclass-specific tryptic peptides (i.e., surrogate peptides) in one single sample
injection and run, which only took 20 min. Last but not the least, the combination of NPA-assisted
antibody purification and LC-MS/MS analysis can achieve profiling of antibodies and other
proteins. As mentioned and investigated in Chapter 2, the antibody repertoire has the potential to
be an information bank containing an individual's antigen exposure history, which may facilitate
for evaluation on immunity, autoimmunity and cancer detection.

4.2 Experimental
4.2.1 Chemicals and materials
Human serum albumin (HSA, lyophilized powder) and human serum (from human male AB
plasma, USA origin, sterile-filtered) were from Sigma-Aldrich. ProteoExtract® albumin removal
kit was from EMD Millipore. Protein A magnetic beads (MBA) were obtained from New England
Biolabs (NEB) Inc.. Magnetic nanoparticles bearing HSA specific nanopockets (NPHSA) and
protein A-like nanopockets (NPA) were developed as reported. 13 Sequencing grade modified
trypsin was obtained from Promega Corporation. Water, acetonitrile (ACN), formic acid (FA),
acetone, and ammonium acetate (NH4Ac) were all of LC-MS reagents from Sigma-Aldrich.
Myoglobin (Mb, from horse heart) and other chemicals were also from Sigma-Aldrich unless
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otherwise noted. All solutions were prepared using 18 MΩ cm water purified by passing through
a Hydro Service and Supplies purification system. Trypsin was reconstituted and aliquoted in 0.3%
acetic acid solution for storage (-80°C) while the working buffer was 50 mM NH4Ac and pH was
adjusted to 8.5 using ammonia.
Mouse serum was kindly provided by Prof. Dr. Dharamainder Choudhary from University of
Connecticut Health Center.

4.2.2 Sample preparation
For the analysis of intact HSA, all samples started with 20 µL undepleted human serum and went
through different depletion procedures as reported.5 The resulting samples were then transferred
to Amicon® ultracentrifugal filter units (EMD Millipore) with a molecular weight cut off (MWCO)
of 3 kDa for buffer exchange and desalting. In detail, the filter unit was first centrifuged at 13,000
rpm under 4°C for 30 min, then 500 µL of 0.2% FA was added into the inner tube. Above step was
repeated three times. Finally samples were diluted with 0.2% FA to bring them into the same
volume and were subjected to LC-MS analyses.
For the analysis of digested proteins and antibodies, pellet digestion was used for tryptic peptide
preparation with minor modification. 14 , 15 First, BCA (bicinchoninic acid) protein assay was
performed on each samples to obtain the information of total protein concentration.16 After spiking
1 mg mL-1 horse heart myoglobin (Mb) as an internal standard to each sample, urea was added to
give the solutions of 6 M urea. Protein reduction was carried out by adding 2 µL of 200 mM DTT
(dithiothreitol) to the sample solution, followed by a 30 min incubation at room temperature. Then
the samples bearing reduced free thiol groups were alkylated by utilizing 2 µL of 1 M
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iodoacetamide (IAA) in the darkness for another 30 min at room temperature. Excess IAA was
further neutralized by 10 µL of 200 mM DTT solution. The resulting samples were chilled by
adding cold (-20°C) acetone; another 5 volumes of cold acetone were then added sequentially,
followed by overnight incubation at -20°C. After centrifugation at 13,000 rpm under 4°C for 30
min, the supernatants were discarded and the resulting pellets were washed with 86% acetone three
times. The pellets were then air-dried and digested with trypsin in a trypsin/protein (w/w) ratio of
1:100 for 18 hours. The trypsin digestion was stopped by adding 10% FA to approximately pH 3,
and then the tryptic peptides were filtered through an AcroPrep™ 96-well filter plate (MWCO =
3 kDa, Pall Corporation) and subjected to LC-MS/MS analysis.
All samples (either for the analysis of intact HSA or for the analysis of digested proteins and
antibodies) were pipetted in autosampler vials containing glass inserts (150 µL low volume insert
with plastic spring, Waters Corporation).

4.2.3 LC-MS instrumentation and analysis
For the analysis of intact HSA form samples, a Thermo Scientific Dionex Ultimate 3000 UPLC
system interfaced to a QSTAR Elite mass spectrometer (AB Sciex) was constructed. Protein
separation was conducted using a Thermo Scientific ProSwift RP-10R monolithic 50 mm × 1.0
mm i.d. column. The column was run with a flow rate of 50 µL min-1 and a column temperature
of 60°C. The gradient used was listed in Table 4.1, where solvent A is 98.8% water, 1.0% ACN
and 0.2% FA, and solvent B is 1.0% water, 98.8% ACN and 0.2% FA.
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Table 4.1 UPLC gradient used for protein separation and peptide separation.
the analysis of intact HSA

the analysis of digest samples

time, min

%B

time, min

%B

0
2
11
12
12.5
15

10
10
80
80
10
10

0
3
23
23.5
26
26.1
30

1
1
40
90
90
1
1

The QSTAR mass spectrometer was operated with a TurboIonSpray ion source in positive mode.
Key parameters of time-of-flight (TOF) MS instrument were set as curtain gas (CUR) = 20
arbitrary units, ionspray voltage (IS) = 5000 V, temperature (TEM) = 300°C, ion source gas 1
(GS1) = 22 arbitrary units, ion source gas 2 (GS2) = 15 arbitrary units, declustering potential (DP)
= 70 V, focusing potential (FP) = 250 V, declustering potential 2 (DP2) = 20 V, ion release delay
(IRD) = 127.3 arbitrary units, ion release width (IRW) = 55.2 arbitrary units, m/z ratio range = 800
~ 2000.
For the analysis of digest samples, the Thermo Scientific Dionex Ultimate 3000 UPLC interfaced
to either an AB Sciex 4000 QTRAP mass spectrometer (for HSA quantification purpose) or a
Thermo Scientific TSQ Quantiva triple quadrupole mass spectrometer (for antibody quantification
purpose) was constructed. Peptide separation was conducted using a Jupiter C18 column (150 ×
0.50 mm, 5 µm, Phenomenex), which was run with a flow rate of 15 µL min-1 and a column
temperature of 35°C. The gradient used was listed in Table 4.1, while solvent A and B were the
same as above. Both mass spectrometers were operated in the positive mode.
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In the HSA relative quantification, multiple reaction monitoring (MRM) was operated on the 4000
QTRAP mass spectrometer, which ran six m/z transitions (precursor/product ion pairs) with dwell
time of 0.15 s for each m/z transitions simultaneously (Table 4.2). Key parameters of MRM-MS
on QTRAP were set as curtain gas (CUR) = 20 arbitrary units, collision gas (CAD) = medium,
ionspray voltage (IS) = 5000 V, temperature (TEM) = 300°C, ion source gas 1 (GS1) = 20 arbitrary
units, ion source gas 2 (GS2) = 40 arbitrary units, entrance potential (EP) = 10 V, collision cell
exit potential (CXP) = 10 V, interface heater (ihe) = on.

Table 4.2 MRM transitions and parameters used in the analysis of digest samples on QTRAP MS
transition mass filter[c], DP[d],
V
m/z

CE[e], Role[f]
V

human serum
LVNEVTEFAK
albumin
(HSA)

575.658  938.018 (y8)

73.1

28.5

Quantification

575.658  823.915 (y7)

73.1

28.5

Confirmation

575.658  694.800 (y6)

73.1

28.5

Confirmation

horse heart
LFTGHPETLEK
myoglobin
(Mb)

636.721  1012.100 (y9) 77.5

32.0

Quantification

636.721  910.996 (y8)

77.5

32.0

Confirmation

636.721  716.804 (y6)

77.5

32.0

Confirmation

protein[a]

selected peptide[b]

[a] the name of protein; [b] peptide sequence for protein quantification; [c] the precursor ion m/z
 the product ion m/z for protein quantification; [d] declustering potential (DP), the voltage
applied to the orifice that helps to prevent the ions from clustering together; [e] collision energy
(CE), voltage applied to the collision cell; [f] purpose of setting each m/z transition.
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In the antibody relative quantification, multiple reaction monitoring (MRM) was operated on the
TSQ Quantiva mass spectrometer, which ran over 30 m/z transitions (precursor/product ion pairs)
in a cycle time of 1 second (Table 4.3). Key parameters of MRM-MS on Quantiva were set as ion
source type = H-ESI, spray voltage (static) positive ion = 3900 V, sheath gas = 20 arbitrary units,
aux gas = 7 arbitrary units, sweep gas = 2 arbitrary units, ion transfer tube temperature = 300°C,
vaporizer temperature = 33°C, APPI lamp = not in use; and the MRM properties were set as use
cycle time = checked, cycle time = 1 s, use calibrated RF lens = checked, Q1 resolution (FWHM)
= 0.7, Q3 resolution (FWHM) = 0.7, CID gas = 1.5 mTorr, source fragmentation = 0 V, chrom
filter = 3 s, Display retention time = unchecked

Table 4.3 MRM transitions and parameters used in the analysis of serum samples on Quantiva MS
protein

selected peptide

generic
human IgG

DTLMISR

human IgG1

GPSVFPLAPSS
K

CE,
V

transition mass filter, m/z

Role

16.5

418.220  506.276 (y4)
418.220  619.360 (y5)
418.220  375.235 (y3)

Quantification
Confirmation
Confirmation

22.5

593.826  699.404 (y7)
593.826  1032.572 (y10)
593.826  846.472 (y8)

Quantification
Confirmation
Confirmation

412.747  654.382 (y6)
412.747  557.329 (y5)
412.747  486.292 (y4)
472.901 (+3)  534.278 (y102+)
472.901 (+3)  615.809 (y112+)
472.901 (+3)  484.743 (y92+)

Quantification
Confirmation
Confirmation
Quantification
Confirmation
Confirmation

415.734  660.356 (y6)
415.734  563.304 (y5)
415.734  476.271 (y4)

Quantification
Confirmation
Confirmation

human IgG2

GLPAPIEK

human IgG3

WYVDGVEVH
15.5
NAK

human IgG4

GLPSSIEK

16.4

16.5
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Table 4.3 continued
protein

CE, V

transition mass filter, m/z

Role

22.9

607.683  786.410 (y7)
607.683  1027.553 (y9)
607.683  914.469 (y8)

Quantification
Confirmation
Confirmation

15.5

472.901 (+3)  534.278 (y102+)
472.901 (+3)  615.809 (y112+)
472.901 (+3)  484.743 (y92+)

Quantification
Confirmation
Confirmation

16.5

415.734  660.356 (y6)
415.734  563.304 (y5)
415.734  476.271 (y4)

Quantification
Confirmation
Confirmation

607.683  786.410 (y7)
607.683  1027.553 (y9)
607.683  914.469 (y8)
455.214  590.305 (y5)
455.214  794.394 (y7)
455.214  737.373 (y6)

Quantification
Confirmation
Confirmation
Quantification
Confirmation
Confirmation

21.9

575.311  937.463 (y8)
575.311  823.420 (y7)
575.311  694.377 (y6)

Quantification
Confirmation
Confirmation

19.0

490.751  562.273 (y5)
490.751  824.405 (y7)
490.751  661.342 (y6)

Quantification
Confirmation
Confirmation

human
apolipoprote ATEHLSTLSEK 13.5
in A1 (Apo
A1)

405.878  577.319 (y5)
405.878  777.435 (y7)
405.878  476.271 (y4)

Quantification
Confirmation
Confirmation

generic
mouse
IgG[a]

416.742  644.398 (y6)
416.742  543.350 (y5)
416.742  456.318 (y4)

Quantification
Confirmation
Confirmation

human IgA

selected peptide
WLQGSQELPR

WYVDGVEVH
human IgG3
NAK

human IgG4 GLPSSIEK

human IgA

WLQGSQELPR

22.9

human IgM

DGFFGNPR

17.8

human
serum
albumin
(HSA)
human
haptoglobin
(Hp)

LVNEVTEFAK

VGYVSGWGR

TSTSPIVK

16.5

[a] Since mouse IgG antibodies bearing κ light chain constitute 99% of total mouse IgG
antibodies,17 this “TSTSPIVK” peptide derived from mouse IgG κ light chain was selected for
quantification of total mouse IgG antibodies.
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Table 4.3 continued
protein
mouse IgG1

mouse
IgG2aa
mouse
IgG2ab
mouse
IgG2b

mouse IgG3

mouse IgA

mouse IgM
mouse serum
albumin
(MSA)
mouse
haptoglobin
(Hp)

selected peptide
VNSAAFPAPIE
K

DLPAPIER

ALPSPIEK

DLPSPIER

ALPAPIER

WNSGASFK

DGFSGPAPR

QTALAELVK

VGYVSGWGR

mouse
apolipoprotein LSPVAEEFR
A1 (Apo A1)
horse heart
myoglobin
(Mb)

CE, V

transition mass filter, m/z

Role
Quantification
Confirmation
Confirmation

23.5

622.337  654.382 (y6)
622.337 872.488 (y8)
622.337 801.451 (y7)

17.8

455.753  514.298 (y4)
455.753  682.388 (y6)
455.753  585.3355 (y5)

Quantification
Confirmation
Confirmation

16.9

427.752  670.377 (y6)
427.752 573.3243 (y5)
427.752 486.2922 (y4)

Quantification
Confirmation
Confirmation

18.1

463.750  698.383 (y6)
463.750  601.330 (y5)
463.750  514.298 (y4)

Quantification
Confirmation
Confirmation

17.1

433.758  514.298 (y4)
433.758  682.388 (y6)
433.758  585.335 (y5)

Quantification
Confirmation
Confirmation

17.6

448.716  596.304 (y6)
448.716 509.272 (y5)
448.716  452.250 (y4)

Quantification
Confirmation
Confirmation

17.7

452.219  584.315 (y6)
452.219  731.384 (y7)
452.219  497.283 (y5)

Quantification
Confirmation
Confirmation

18.9

486.789  559.345 (y5)
486.789  672.429 (y6)
486.789  488.308 (y4)

Quantification
Confirmation
Confirmation

19

490.751  562.273 (y5)
490.751  824.401 (y7)
490.751  661.342 (y6)

Quantification
Confirmation
Confirmation

20.1

524.277  651.310 (y5)
524.277  847.431 (y7)
524.277  750.378 (y6)

Quantification
Confirmation
Confirmation

636.335  1011.511 (y9)
636.335  910.463 (y8)
636.335  716.382 (y6)

Quantification
Confirmation
Confirmation

LFTGHPETLEK 23.9
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4.2.4 Data analysis
The mass spectra of HSA protein were deconvoluted by the Bayesian protein reconstruct tool
(Bioanalyst QS 1.1 software package). Key parameters for protein reconstruction were set as start
mass = 10,000 Da, stop mass = 90,000 Da, step mass = 1 Da, S/N threshold = 20 Da, adduct =
Hydrogen.
A freely-available, open-source bioinformatics tool, Skyline1, was used to generate the transition
list for MRM-MS (Table 4.2 and 4.3). The obtained MRM data were then imported back to Skyline
application for the determination of peak areas from each of the monitored transitions. The 1st
ranking peak area of each peptide transition is used for protein quantification (Table 4.2 and 4.3).

4.3 Results
4.3.1 HSA protein chromatographic separation and quantification
Due to the complex nature of serum, separation of serum HSA from serum samples using UPLC
dramatically improves the MS characterization of HSA itself. Herein, samples containing
undepleted and depleted human serum, and purified standard albumin from human serum were
introduced to the UPLC column under gradient conditions. As indicated by the standard, HSA
protein was eluted at around 11.5 min from the total ion chromatogram (TIC) using the TOF mass
analyzer in positive mode (Figure 4.1). In the TIC of undepleted serum, a major peak was also
observed at approximately 11.5 min, indicating the most abundant HSA proteins were separated
from other serum proteins. No well-defined peak was observed in the TIC of depleted serum,
showing the abundant serum HSA must be removed after the treatment of NPHSA and PEHSA.
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Figure 4.1 Total ion chromatograms (TICs) of samples from (A) undepleted human serum,
albumin depleted human serum via (B) specially constructed HSA binding magnetic nanoparticles
(NPHSA) and (C) commercial product ProteoExtract® albumin removal kit (PEHSA), and (D)
purified standard albumin from human serum using Thermo Scientific ProSwift RP-10R
monolithic column. The peak at approximately 11.5 min indicated the presence of HSA proteins.

The TICs in Figure 4.1, however, provide limited information about serum albumin depletion since
other proteins might elute simultaneously with HSA and contributed to the intensity, leading to
difficulty in quantitative interpretation. The positive-ion mass spectra were then acquired over m/z
ratio of 800 ~ 2000 from TICs of undepleted serum and standard HSA, showing a typical charge
distribution observed for large proteins with the addition of tens of protons (Figure 4.2). The most
abundant charge state (z = +52), as zoomed in the inserts, pictures the two most abundant peaks
with serval less abundant peaks of the intact HSA, indicating several post-translational
modifications (PTMs) of the proteins. The calculated molecular mass of HSA is estimated as 66.5
kDa (m/z of 1280 × z of +52 = 66,560), which agrees with the literature reports.28
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Figure 4.2 Average electrospray mass spectra over the HSA elution time (11.5 ~ 12.0 min) from
the total ion chromatograms in Figure 4.1. Samples were from (A) undepleted human serum, and
(B) standard HSA. Both inserts were zoomed pictures of the most abundant charge state (z = +52),
where the observed peak pattern represents the several post-translational modifications (PTMs) of
the HSA proteins.

Although the fingerprints of HSA are observed in Figure 4.2, the specific m/z ratio for HSA is
difficult to determine due to many PTMs happened to HSA molecules (Figure 4.2, inserts). Such
an m/z, corresponding to the most intense peak in the average mass spectrum over the HSA elution
time (11.5 ~ 12.0 min) in individual TICs, was used to generate the extracted ion chromatograms
(XICs, Figure 4.3), respectively. The XICs, focusing on specific m/z ratio of HSA, give an
improved peak resolution compared to TICs and enable the semi-quantification of HSA for each

94

sample. Thus the peak areas have been integrated for HSA relative quantification and the amount
of HSA proteins in undepleted serum is estimated as ten times of that in the depleted serum samples
after treatment of either NPHSA or PEHSA, showing the albumin removal capacity (90% removed)
of NPHSA is comparable to the commercial product PEHSA.

Figure 4.3 Extracted ion chromatograms (XICs) of samples from (A) undepleted human serum,
albumin depleted human serum via (B) specially constructed HSA binding magnetic nanoparticles
(NPHSA) and (C) commercial product ProteoExtract® albumin removal kit (PEHSA), and (D)
purified standard albumin from human serum using Thermo Scientific ProSwift RP-10R
monolithic column. The peak at approximately 11.5 min indicated the presence of HSA proteins.
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4.3.2 HSA post-translational modification (PTM) identifications
The intact mass of two major peaks and a series of less abundant peaks of standard and serum
HSA, as indicated in inserts of Figure 4.2, are resolved using Bayesian protein reconstruct tool
(Bioanalyst QS 1.1 software package). The deconvoluted mass spectra were obtained from either
serum HSA (Figure 4.4A) or standard HSA (Figure 4.4B). The assignment of the peaks was based
on previously reported characterizations,27,28 mainly taking the oxidative modifications and
glycation on HSA molecules (Table 4.3) into account. Almost all common PTMs on HSA
molecules were identified in accordance with previous literature report,27,28 showing the
heterogeneity of HSA in human serum.

Figure 4.4 Deconvolution results of the (A) serum HSA and (B) standard HSA using Bayesian
protein reconstruct tool (Bioanalyst QS 1.1 software package). Each peak is labeled with number
or letter, and identified to a certain HSA PTM in Table 4.3.
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Table 4.4 HSA post-translational modifications (PTMs) identified in Figure 4.4.
serum HSA

standard HSA

expected
molecular
mass, Da

estimated HSA
structure

observed
molecular
mass, Da

the peak in
Figure 4.4A

observed
molecular
mass, Da

the peak in
Figure 4.4B

66439

HSA-SH

66441

1

66434

a

(+32)

HSA-SO2H

N/A

N/A

66471

b

(+48)

HSA-SO3H

66481

2

N/A

N/A

(+119)

Cys-HSA

66559

3

66555

c

(+162)

HSA-Glyc

66607

4

66600

d

(+222)

Cys-HSA-(SO3H)2

66659

5

N/A

e

(+281)

Cys-HSA-Glyc

66719

6

66720

f

4.3.3 Relative quantification of HSA using surrogate peptide approach
Besides the intact protein approach used above, the surrogate peptide approach was also conducted
for HSA relative quantification in the same samples. In detail, the undepleted and depleted serum
samples were individually diluted into the same volume, spiked with myoglobin (Mb) as internal
standard, digested by trypsin and sent to a triple quadrupole mass spectrometer (QTRAP) for LCMS/MS analysis using MRM method which was monitoring three transitions for each peptides
(Table 4.2 and Figure 4.5).
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Figure 4.5 A representative of MRM chromatograms containing three transitions for a single
tryptic peptide from (A) HSA; (B) Mb.

The peak area of the peptide from Mb, as an internal standard, was used to normalize the signals
of HSA peptide in the MRM chromatographs (Figure 4.6A). Defining the signal of HSA protein
in undepleted serum as 100%, the signals of HSA in depleted samples from NPHSA and PEHSA
treatment were found and compared (Figure 4.6B).

Figure 4.6 Comparison of HSA removal capability using NPHSA and PEHSA. (A) Representative
normalized MRM chromatogram of HSA peptide (LVNEVTEKAK) derived from undepleted
human serum and albumin depleted human serum by NPHSA and PEHSA; (B) Relative percentage
of HSA protein in undepleted human serum, albumin depleted human serum by NPHSA and PEHSA,
respectively, assuming the percentage of HSA in undepleted serum is 100%.
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4.3.4 MS-based surrogate peptide approach for multiple serum proteins
In order to do relative quantification of antibodies isolated by protein A-like nanoparticles (NPA),
a conventional LC-MS/MS (MRM) method was developed for relative quantification of serum
proteins using surrogate peptide approach. Here, human serum from commercial sources was used
as standards for all kinds of abundant human serum proteins, which include four isotypes of human
IgG antibodies (IgG1, 2, 3, and 4 antibodies), IgA and IgM antibodies, human serum albumin
(HSA), haptoglobin (Hp) and apolipoprotein A1 (Apo A1). The human serum sample was spiked
with myoglobin (Mb) proteins, denatured by urea, reduced by DTT and alkylated by IAA. The
sample further went through acetone precipitation and pellet digestion; the resulting peptides were
analyzed by LC-MS/MS using MRM method which was monitoring three transitions for each
peptides (Table 4.3 and Figure 4.7).
The surrogate peptides were selected based on previous reports12,18-21 with the combination of the
actual LC-MS/MS results of these peptides and the criteria described in the Introduction section.
Similarly, the fragmentation mass transitions of each surrogate peptide were also based on the
previous reports and the actual LC-MS/MS results, i.e., we chose one mass transition which gave
the largest peak area for the protein quantification purpose (Figure 4.8) and other two transitions
for confirmation purpose (Table 4.3,Figure 4.7 and 4.8).
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Figure 4.7 The representative MRM chromatograms containing three transitions for the surrogate
tryptic peptide from each protein for protein identification and quantification. The peptides and
proteins include: 1, DTLMISR from all four human IgG antibodies; 2, GPSVFPLAPSSK from
human IgG1 antibodies; 3, GLPAPIEK from human IgG2 antibodies; 4, WYVDGVEVHNAK
from human IgG3 antibodies; 5, GLPSSIEK from human IgG4 antibodies; 6, WLQGSQELPR
from human IgA antibodies; 7, DGFFGNPR from human IgM antibodies; 8, LVNEVTEFAK from
human serum albumin (HSA); 9, VGYVSGWGR from human haptoglobin (Hp); 10,
ATEHLSTLSEK from human apolipoprotein A1 (Apo A1); 11, LFTGHPETLEK from horse heart
myoglobin (Mb) as internal standard.
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Figure 4.8 A representative extracted ion chromatogram (XIC) of 10 MRM transitions (peaks) of
eleven tryptic peptides from ten different kinds of proteins in myoglobin (Mb) spiked human serum
sample. The peptides include: 1, ATEHLSTLSEK from human apolipoprotein A1 (Apo A1); 2:
GLPSSIEK from human IgG4 antibodies; 3, DTLMISR from all four human IgG antibodies; 4,
LFTGHPETLEK from horse heart myoglobin (Mb) as internal standard; 5: GLPAPIEK from
human IgG2 antibodies; 6, VGYVSGWGR from human haptoglobin (Hp); 7, DGFFGNPR from
human IgM antibodies; 8, WYVDGVEVHNAK from human IgG3 antibodies; 9, WLQGSQELPR
from human IgA antibodies; 10, LVNEVTEFAK from human serum albumin (HSA); 11,
GPSVFPLAPSSK from human IgG1 antibodies. The relative intensity of peak 10 (HSA) was
scaled down 10-fold.

4.3.5 Human serum analyses
The human serum, containing four subclasses of human IgG antibodies, i.e., IgG1, IgG2, IgG3,
and IgG4 antibodies, and other serum proteins, e.g., human IgA and IgM antibodies, HSA, Hp,
and Apo A1 were treated using protein A-like magnetic nanoparticles (NPA) and commercial
protein A magnetic beads (MBA), respectively. The NPA and MBA with serum proteins captured
were further magnetically separated, washed, and treated using 0.2 M glycine-HCl buffer (pH 2.5).
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Thus the captured serum proteins were isolated out in a more pure eluate form. To examine the
stability and reusability of these magnetic particles, both NPA and MBA particles were regenerated
and reused in total three times to obtain the depleted serum and recovered proteins. The untreated
and depleted human serum samples as well as recovered serum proteins were individually diluted
into the same volume, spiked with Mb, digested by trypsin and sent to the LC-MS/MS analyses.
As mentioned in the previous sections, one unique peptide from each human serum protein (total
IgG, IgG1, IgG2, IgG3, IgG4, IgA, IgM, HSA, Hp, Apo A1, and Mb) was selected for
quantification purpose. The peak area from the peptide of Mb, as an internal standard, was used to
normalize the signals of other peptides in the MRM chromatographs. Defining the signals of each
protein in untreated human serum as 100%, the signals of the same proteins in depleted and
recovered samples from either NPA or MBA treatment were found and compared.
As the most abundant antibodies in the human serum, total human IgG antibodies were first
investigated in the samples before and after either NPA or MBA treatments. The performance of
NPA is surprisingly good, which continuously recovered over 30% total human IgG antibodies per
mg NPA while MBA recovered around 30% total human IgG antibodies per mg MBA (Figure 4.9A).
Meanwhile, the sum of human IgG antibodies recovered and left in the samples treated by NPA
particles almost agrees with 100% per 2 mg NPA (Figure 4.9B), indicating almost all human IgG
antibodies captured by 2 mg NPA were recovered using 0.2 M glycine-HCl elution buffer (pH 2.5).
There is no statistically significant difference (t-test, P > 0.01) between each usage of either MBA
or NPA in term of recovered or leftover human IgG antibodies, although there was a slightly
decrease in the relative percentage of human IgG antibody recovery after each usage.
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Figure 4.9 (A) Comparison of recovered total IgG antibodies per mg particle from human serum
using 25 μL MBA (red) and 2 mg NPA (blue) in total three-time usages. (B) Relative percentage of
total IgG antibodies recovered by 2 mg NPA (blue) and leftover after 2 mg NPA treatment (green).
The percentage of total IgG antibodies in untreated human serum is defined as 100.

In agreement with results of total human IgG antibodies, NPA recovered similar percentage of
human IgG1, IgG2, IgG3, and IgG4 antibodies compared to 25 μL MBA in term of per mg particles,
respectively (Figure 4.10). In detail, NPA recovered 33±3% total IgG antibodies, 38±3% IgG1,
21.7±1.2% IgG2, 34±3% IgG3 and 15.1±0.9% IgG4 antibodies out of human serum per mg
particle, while MBA recovered 29±4% total IgG antibodies, 30±2% IgG1, 24.9±1.5% IgG2, 30±3%
IgG3, and 20.3±1.1% IgG4 antibodies per mg particle. Besides IgG antibodies, the particles also
captured other abundant antibodies such as IgA and IgM antibodies, but the IgD or IgE antibodies
were not detectable here due to their extremely low abundance. NPA recovered 9.4±0.8% IgA and
30±3% IgM antibodies while MBA isolated 16.2±1.5% IgA and 47±4% IgM antibodies, both of
which are per mg particle and comparable to the percentages of recovered IgG antibodies. The
undesired capture of non-antibody proteins, such as HSA, Hp and Apo A1, was also monitored.
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Nevertheless, only 3.0±0.2% HSA, 2.0±0.3% Hp, and 4.6±0.3% Apo A1 were recovered by 1 mg
NPA, but, 12.4±0.9% HSA, 4.4±0.6% Hp, and 13.2±1.1% Apo A1 were isolated by 1 mg MBA,
showing both particle exhibit specificity for immunoglobulins.

Figure 4.10 Relative percentage of each human serum protein recovered by commercial MBA (red,
25 μL) and home-made NPA (blue, 2 mg), assuming the percentage of each protein in untreated
human serum is 100. IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M;
HSA: human serum albumin; Hp: haptoglobin; Apo A1: apolipoprotein A1.

4.3.6 Mouse serum analyses
Mouse antibodies are one of major commercialized antibodies besides human and humanized
antibodies. Here, similar to human serum, a mouse serum sample was used and treated with NPA
and MBA to examine their performance of recovering certain mouse antibodies from serum.
Similar to the previous results, surrogate peptide approach was used, and a similar LC-MS/MS
method using MRM mode was developed (Table 4.3, Figure 4.11 and 4.12). Again, NPA gave a
better performance of mouse antibodies recovery than MBA (Figure 4.13).
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Figure 4.11 The representative MRM chromatograms containing three transitions for a single
tryptic peptide from each protein for protein identification and quantification. The peptides and
proteins include: 1, TSTSPIVK from mouse IgG κ light chain (treated as all kinds of mouse IgG
antibodies, see Table 5.2 footnote); 2, VNSAAFPAPIEK from mouse IgG1 antibodies; 3,
DLPAPIER from mouse IgG2aa antibodies; 4, ALPSPIEK from mouse IgG2ab antibodies; 5,
DLPSPIER from mouse IgG2b antibodies; 6, ALPAPIER from mouse IgG3 antibodies; 7,
WNSGASFK from mouse IgA antibodies; 8, DGFSGPAPR from mouse IgM antibodies; 9,
QTALAELVK from mouse serum albumin (MSA); 10, VGYVSGWGR from mouse haptoglobin
(Hp); 11, LSPVAEEFR from mouse apolipoprotein A1 (Apo A1); 12, LFTGHPETLEK from
horse heart myoglobin (Mb) as internal standard.
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Figure 4.12 A representative XIC of 12 tryptic peptides from 11 different kinds of mouse proteins
in Mb spiked mouse serum sample. The peptides include: 1, TSTSPIVK (mouse IgG κ light chain);
2, DGFSGPAPR (IgM antibodies); 3, WNSGASFK (IgA antibodies); 4, LFTGHPETLEK (Mb);
5, ALPSPIEK (IgG2ab antibodies); 6, ALPAPIER (IgG3 antibodies); 7, DLPAPIER (IgG2aa
antibodies); 8, DLPSPIER (IgG2b antibodies); 9, VGYVSGWGR (mouse Hp); 10, LSPVAEEFR
(mouse Apo A1); 11, VNSAAFPAPIEK (IgG1 antibodies); 12, QTALAELVK (MSA). The
relative intensity of peak 12 (MSA) was scaled down 10-fold.

Figure 4.13 Relative percentage of each mouse serum protein recovered by commercial MBA (red,
25 μL) and home-made NPA (blue, 2 mg), assuming the percentage of each protein in untreated
mouse serum is 100. MSA: mouse serum albumin.
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4.4 Discussion
Human serum albumin (HSA) is the most abundant protein in human blood plasma/serum,
constituting over 50% of total serum proteins with concentrations of approximately 40 mg mL-1
(0.6 mM).22 It is responsible for a stable pH, oncotic pressure, oxidant/antioxidant balance, and
other critical physiological criteria in the blood. Due to its extraordinary ligand binding capacity,
HSA also represents the dominant carrier for bilirubin, metal ions, hormones, fatty acids, and other
important, biologically-relevant compounds.23 It affects the pharmacokinetics of many drugs but
also emerges as a promising tool for therapeutic drug delivery since it has a serum half-life of
approximately 20 days.24
The nascent HSA is produced in the liver from a single gene as pre-pro-albumin, of which Nterminal peptide is truncated in the rough endoplasmic reticulum. The resulting product, proalbumin, is further transported to and cleaved in the Golgi apparatus before eventually secreted
out of the cell as the mature HSA. Such mature HSA consists of 585 amino acids, which mostly
present α-helices and loops, resulting in three homologous domains with a monomeric structure
resembling a heart shape.25 The mature HSA molecule has 17 disulfide bridges from 34 cysteine
(Cys) residues and one free Cys residue presenting free sulfhydryl group at position 34 (Cys34).
The free sulfhydryl group features HSA one of the most important participants against reactive
oxygen species (ROS) in the extracellular environment. 26 As a result, increased oxidative
modifications of HSA with free Cys, homocysteine (Hcy), and glutathione (GSH), would be
associated with suboptimal health status or even diseases, including gestational diabetes mellitus27,
alcoholic hepatitis28, cirrhosis29, etc. Besides oxidative modifications on free sulfhydryl group of
Cys34, glycation by non-enzymatic attaching reducing (reactive) carbohydrate to amine groups of
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lysine (Lys) residues is another major modification on HSA proteins.30 Thus, besides glucose and
glycated hemoglobin (hemoglobin A1c, HbA1c), the glycated HSA (glycated albumin, GA) is one
of the biomarkers that is used to ascertain glycemic control in diabetic patients.31
Despite the critical role of HSA associated with diseases, thousands of other biomolecules are
found to be indicators of critical biological processes and/or disease states. And these biomolecules
can also be applied in many fields such as disease diagnosis, therapeutic monitoring, and drug
development. To a large extent, the new biomolecule markers can be discovered by serum and
plasma proteomics, using various gel electrophoresis approaches and/or liquid chromatographymass spectrometry (LC-MS) analysis. The dynamic range of protein concentrations in
serum/plasma proteomes exceeds 10 orders of magnitude and the high abundant proteins often
mask the lower abundant proteins and serve as a major source of non-specific noise in those
proteome assays.
In this chapter, both top-down and bottom-up MS strategies were used for the analysis of HSA
protein in the samples of human serum with/without albumin depletion. Both strategies can fulfill
the analysis task, include protein identification and quantification. The emerging top-down
approach is aiming at the intact protein while the better-established bottom-down is analyzing
peptide fragments derived from digestion of intact proteins.
The top-down MS analyses of intact HSA is a good practice of HSA quantification, which is a
“true” measurement of the whole protein with straightforward sample preparation steps. Although
the current approach is still limited to the analysis of small proteins (e.g. of which molecular mass
less than 20 kDa), out results indicate that it is still feasible for the analysis of protein with 66.5
kDa molecular mass. Especially, top-down MS strategy is much more useful in identification of
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different HSA isoforms, i.e., the HSA derivatives after biotransformation and post-translational
modifications (Figure 4.4 and Table 4.3). However, it is impractical and unnecessary to measure
all kinds of isoforms and then add them up for quantification purpose. As a matter of fact, using
specific unique peptides which shared by all the HSA isoforms would be a good idea. In addition,
large protein separation in the LC column is not well standardized, and it is harder to develop such
LC method compared to peptide LC separation. Although HSA was successfully separated here,
it is mainly due to the fact that HSA is the most abundant protein in the serum, so it gave a welldefined peak in the chromatograph (Figure 4.1 and 4.3). The continuous improvement in MS
technology, chromatographic separation, and sample preparation techniques will enable the
broader application of top-down approach for bioanalysis of larger proteins in the future.32,33
The bottom-up MS analyses of HSA using surrogate peptide is a well-established method for
protein quantification, although it takes more sample preparation steps including protein digestion
and sample clean-up. Here, instead of conventional in-solution digestion method, we employed a
relatively simple sample preparation method which is called pellet digestion.14,15 In detail, proteins
from human serum went through acetone precipitation and become pellet, followed by trypsin
digestion in an MS-compatible buffer, which skips the time-consuming and labor-intensive peptide
desalting steps. Such pellet digestion approach can achieve a good peptide recovery,
reproducibility, and its performance is independent of matrix types.15 Thus, it is well suited in our
application of analyzing proteins from serum sample as it provides highly accurate and precise
quantification. The similar results in term of HSA depletion percentage via NPHSA and PEHSA were
observed using either intact protein approach or this surrogate peptide approach featured by pellet
digestion (Figure 4.3 and 4.7). This indicates that the pellet digestion approach is highly robust
and efficient, making it readily adaptable to quantify multiple serum proteins simultaneously (see
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following sections). In addition, the results show that the non-isotopically labeled, exogenous
proteins (i.e., Mb, digested to peptides) act as a good, inexpensive internal standard for relative
protein concentration determination between samples.
The home-made NPA and commercial MBA particles exhibited a similar binding pattern for the
abundant serum antibodies (e.g. IgG, IgA and IgM antibodies) and non-antibody proteins. Thus,
NPA should have many Fc-binding, protein A-like nanopockets as we expected. General speaking,
NPA had a better performance than MBA in term of higher protein binding/recovery capacity as
described in the result sections (Figure 4.9, 4.10, and 4.13). The MBA particles were directly
purchased and had a diameter of 2 μm. However, little information is known due to it is proprietary,
such as the MBA particle mass per mL stock solution. So we estimated as 17.2±0.3 mg mL-1 by
drying a certain amount of particles and weighing them on a balance. The relative percentage
recovery of IgG antibodies are comparable between NPA and MBA in terms of per mg particle, but
clearly NPA has more specificity for IgG antibodies than IgA or IgM antibodies then MBA (Figure
4.9, 4.10, and 4.13). It is due to the nanopocket on NPA is rigid, compared to protein A which has
five homologous antibody binding domains that would be flexible. Thus, the nanopockets will not
hold the large molecules like IgA and IgM antibodies while protein A still can reach to the Fc
region of these antibodies, which explains why MBA binds more IgA and IgM antibodies than NPA.
Meanwhile, NPA were protected by (PEG)4 coating, which further reduces the non-specific binding
of other serum proteins such as HSA, giving an excellent performance in minimizing undesired
protein recovery.
Although NPA and MBA exhibited similar relative recovery of IgG antibodies per mg particle, the
price of 1 mg particles between them are of significant difference (Table 4.5). The NPA only costs
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23% of MBA, showing great promise in commercial application, not to mention NPA would be
more stable than MBA as no proteins are involved in the final product of NPA.

Table 4.5 Price comparison of NPA and MBA for each run

1 mg NPA
1mg MBA

Magnetic
particles

Template mouse Other
IgG2a protein
chemicals

Total

$ 1.665

$ 0.715 (5 μg)

$ 2.40

$ 0.20

-------------------Not available-------------------

$ 10.35

There are 7.5 ~ 22 mg mL-1 IgG antibodies in normal human serum, thus 20 μL human serum
contains 150 ~ 440 μg of human IgG antibodies.17 In our case, 25 μL MBA recovered 13% IgG
antibodies, which is 19.5 ~ 57.2 μg human IgG antibodies, corresponding to 780 ~ 2,288 μg human
IgG antibodies per mL MBA. The vendor claims that 1 mL of MBA binds over 280 µg (or over 400
µg in the product data card) of human IgG antibodies, which is reasonable. Interestingly, many
vendors indicate that protein A has no or very week binding affinity to human IgG3 antibodies,3436

although herein we found that MBA did not resist to bind to human IgG3 antibodies (Figure 4.9).

The multiple protein A molecules on the MBA surface might help to facilitate the apparent binding
affinity of protein A to human IgG3 antibodies. And actually, there has been a report on the scaleup of human IgG3 antibodies using protein A affinity chromatography.37
Besides above several arguments, much other information could be interpreted by Figure 4.10 in
terms of human antibody recovery. Among the four subclasses of human IgG antibodies, IgG1
antibodies are the most abundant components recovered by NPA and MBA, which agrees with the
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fact that IgG1 antibodies are the most abundant IgG antibodies in the bloodstream (60~70% of
total IgG antibodies) while other IgG antibodies are in relatively low amount.38 The relatively high
percentage of IgA and IgM antibodies recovered by either NPA or MBA particles might be due to
the structural similarities within antibodies as they are all immunoglobulins. Especially IgM
antibodies have the multivalent structures which provide a higher apparent binding affinity. Thus
both NPA and MBA particles exhibited a much higher recovery for IgM antibodies (Figure 4.10).

4.5 Conclusions
In all, we developed a set of LC-MS methods for protein/antibody quantification in the
development of selective nanoparticles. Intact protein approach provided a relatively simple way
to analyze the protein, which did a great job in PTM identifications. Surrogate peptide approach
achieved detection of over ten serum proteins at a single run, which is a great approach for multiple
protein analysis. Our HSA binding nanoparticles removed as many albumins as commercial
depletion columns while the cost is only 2% of the commercial columns. Our antibody binding
nanoparticles can isolate the similar percentage of IgG antibodies from human serum as the
commercial protein A magnetic beads do, but the cost is only 20% of the commercial beads. Thus,
both nanoparticles hold great potentials in protein/antibody isolation or purification.
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